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Abstract 
Next generation sequencing (NGS) technologies provide the potential for developing 
high-throughput and low-cost platforms for medical research and diagnostics, which is 
expected to accelerate the findings of root causes and treatments of human diseases. In 
addition to short read lengths of NGS technology; another limiting factor to clinical 
applications of genomic NGS is downstream bioinformatics analysis. Several challenging 
computation problems have to be solved before we realize the full potential of NGS 
technology. These include management of large quantities of data, efficient analyses, 
fusion of data from various sources, and interpretation of identified variants.  
Endothelial cell (EC) dysfunction is a hallmark of several cardiovascular diseases 
(CVDs). Loss of functional peroxisome proliferator-activated receptor gamma (PPARγ) 
leads to EC dysfunction, and development of pulmonary arterial hypertension (PAH). 
However, the role of PPARγ in angiogenesis in the development of PAH is unknown. In 
this study, RNA sequencing and bioinformatic strategies were used to quantify and reveal 
global gene expression changes associated with loss of PPARγ, in a bid to unravel the 
mechanisms by which PPARγ modulates endothelial homeostasis, regulates angiogenic 
response, and could contribute to the pathobiology of human cardiovascular diseases. 
This study reveals, for the first time in an animal model, that loss of PPARγ leads to 
attenuated ECs migratory capacity and decreased angiogenic potential. Implemented 
bioinformatics approach revealed a novel molecular mechanism and novel downstream 
target gene for PPARγ. Furthermore, this study reports the first genetic analysis of dilated 
cardiomyopathy (DCM) patients in Finland; evaluates the efficacy of NGS in genetic 
diagnostics of DCM patients, and demonstrates the need for a rigorous and clinically 
oriented bioinformatics variant assessment and interpretation strategy. In addition, 
bioinformatics data mining approach was used to evaluate the significance of titin (TTN) 
truncating variants (TTNtv) in the pathogenesis of DCM. 
Mutations in genes encoding sarcomere proteins are the leading cause of DCM, with 
TTNtv accounting for ~21% of DCM cases. Clinical significance of variants in 
cardiomyopathy-associated genes is difficult to assess due to population genetic variation, 
and diagnostic yield of genetic testing is not well understood among DCM patients. 
Moreover, the genetic profile of DCM in Finnish population is poorly understood. In this 
study, a novel targeted resequencing approach, oligonucleotide-selective sequencing (OS-
Seq), was used to investigate the genetic landscape of DCM among Finnish patients, and 
the approach enabled genetic diagnosis for 35.2% of the patients. Notably, 17.2% of 
Finnish DCM patients had TTNtv predicted to cause loss of function. 
Truncating TTN mutations, especially in A-band region, represent the most common 
cause of DCM. Clinical interpretation of these variants can be challenging, as these 
variants are also present in reference populations. Meta analyses of TTNtv reported in 
largest available reference population database, and those identified in accumulated DCM 
cohorts showed that 50 - 53% of TTNtv in the reference population were located in low 
transcript count regions, thus, possessing low likelihood of being disease-causing. On this 
basis, a variant assessment strategy that prioritizes TTNtv affecting at least five transcripts 
of the gene was developed. 
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Abbreviations 
ACMG American college of medical genetics and genomics 
ARVC Arrhythmogenic right ventricular cardiomyopathy 
BMI Body mass index 
BQSR Base quality score recalibration 
BS-seq Bisulfite sequencing 
BWA Burrow Wheeler aligner 
CCDS Consensus coding sequence 
CGH Comparative genomic hybridization 
CHIA-PET Chromatin interaction analysis by paired-end tag sequencing 
ChIP-chip Chromatin immunoprecipitation on chip 
CNVs Copy number variants 
CRT Cardiac resynchronization therapy 
CVD Cardiovascular disease 
DCM Dilated cardiomyopathy 
DNA Deoxyribonucleic acid 
dNTPs Deoxynucleotide triphosphate 
ECs Endothelial cells 
ESC European society of cardiology 
ESP Exome sequencing project 
ExAC Exome aggregation consortium 
fDCM Familial dilated cardiomyopathy 
GRO-seq Global run-on sequencing 
GS Genome sequencing 
HCM Hypertrophic cardiomyopathy 
ICD Implantable cardioverter defibrillator 
iDCM Idiopathic dilated cardiomyopathy 
INDEL Insertion deletion 
LV Left ventricle 
LVEDD Left ventricular end-diastolic diameter 
LVEF Left ventricular ejection fraction 
MAQ Mapping and assembly with quality 
NGS Next generation sequencing 
OMIM Online Inheritance in Man  
PCR Polymerase chain reaction 
PMVEC Pulmonary microvascular endothelial cells  
Ribo-seq Ribosome sequencing 
RNA Ribonucleic acid 
ROI Target region of interest 
SD Standard deviation 
SMRT Single-molecule real-time sequencing 
SNPs Single nucleotide polymorphisms 
SNV Single nucleotide variants 
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SOAP Short Oligonucleotide Analysis Package 
SVs Structural variants 
TFBS Transcription factor binding site 
TFs Transcription factors 
UTR Untranslated regions 
VUS Variants of unknown significance 
WES Exome sequencing 
WES Whole exome sequencing 
WGS Whole genome sequencing 
WT Wild type 
ZMWs Zero-mode wave guides  
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1. Introduction 
Cardiovascular disease (CVD), broadly defined as diseases of the heart and blood vessels, 
is the leading cause of death and a major cause of disability globally [1, 2]. In addition to 
common CVDs with complex environmental and genetic origins, several CVDs including 
cardiomyopathies, channelopathies, aortic diseases, pulmonary arterial hypertension 
(PAH), and lipid disorders display a clearly Mendelian genetic inheritance. 
Dysfunction of Endothelial cells (EC) coupled with angiogenic defects are pathogenic 
paradigm shared by several CVDs. These result in a cascade of events leading eventually 
to poor regeneration of vessels and poor repair mechanisms as seen in PAH. The critical 
role of peroxisome proliferator-activated receptor-gamma (PPARγ) in PAH pathogenesis 
has been elucidated [3-5]. However, the role of PPARγ in angiogenic response is poorly 
understood.  
Dilated cardiomyopathy (DCM), a clinically and genetically heterogeneous cardiac 
disorder characterized by left ventricular dilatation and systolic dysfunction, is a common 
cause of heart failure (HF) and the most common diagnosis in patients referred for cardiac 
transplantation [6, 7]. DCM can occur in response to underlying pathologies including 
valvular dysfunction, hypertension, or myocarditis, or as an idiopathic disorder of the 
myocardium. Among patients with idiopathic DCM, approximately 30 - 50% have 
affected first-degree family members, implying a genetic etiology or predisposition [8]. 
Mutations in genes encoding sarcomere proteins are the leading cause of DCM, with 
truncations of TTN accounting for ~21% of DCM cases [9, 10]. Genetic diagnosis of DCM 
relies on complete sequencing of the gene coding regions, as most pathogenic variations 
are rare. Moreover, clinical significance of variants in cardiomyopathy-associated genes is 
difficult to assess due to population genetic variation; and diagnostic yield of genetic 
testing is not well understood among DCM patients. Furthermore, the frequency of 
truncating TTN mutations in the general population as well as their clinical impacts is not 
well defined. 
High-throughput DNA sequencing has revolutionized our ability to identify genetic 
variations of clinical significance, and a number of large-scale resequencing projects have 
been initiated to extend our knowledge of single nucleotide polymorphisms (SNPs), short 
insertions/deletions (INDELs) and structural variations (SVs), and relate these variants to 
human diseases. Availability of human genomic sequencing is increasing rapidly with the 
recent advancement in NGS technologies. Whole exome sequencing (WES) targeting only 
about 1% of the entire genome yields enormous data whose analyses, interpretation and 
management are quite challenging in the research context for Mendelian disorders 
including cardiomyopathy. Incorporating whole genome sequencing (WGS) into clinical 
practice, especially in dealing with common diseases characterized by complex 
inheritance will therefore result in an exponential growth of complexity [11].  
WGS and WES, though expected to provide a comprehensive analysis, suffer from 
inadequate coverage and poor sequencing quality in 10 - 19% of inherited disease genes, 
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including 9 - 17% of American College of Medical Genetics (ACMG)-reportable genes 
[12]. Furthermore, WGS is still expensive and time consuming. As a cost-effective 
alternative, a variety of target enrichment methods have been developed to capture subsets 
of the genome prior to sequencing. While targeted resequencing of genomic regions 
varying from a few genes up to the entire exomes has been successfully applied for 
discovery of mutations, rare variants and polymorphisms, a number of significant 
technical issues still remain: the experimental protocols are complex, time-consuming and 
error-prone. Oligonucleotide Selective-Sequencing (OS-Seq) is a novel targeted 
resequencing approach, which offers streamlined and flexible workflow and a high 
performance alternative to current capture methods [13]. OS-Seq approach represents an 
effective solution for high-throughput and large-scale genetic analysis. This technology 
gives us a unique possibility for effective and large-scale genetic profiling of 
cardiomyopathy patients such as the presented Finnish DCM cohort (Finn-DCM). 
To establish novel insights to individualized assessment of cardiomyopathy patients 
based on their genetic diagnosis and to evaluate the validity and utility of current genetic 
knowledge, this study aimed to utilize a novel high-quality OS-Seq based targeted 
sequencing panel. More specifically, the goal was to investigate the genetic landscape of 
DCM in the bottlenecked Finnish population characterized by lower frequency of rare 
variants compared to outbred populations, and to evaluate the utility of OS-Seq 
technology as a novel comprehensive diagnostic tool. The overall aim of this study was to 
provide bioinformatics solutions for analyzing (clinical) genomic data originating from 
NGS. The focus was to address genetic variants assessment and interpretative challenges 
plaguing the clinical use of NGS as a diagnostic tool. 
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2. Review of the literature 
2.1 High-throughput techniques and technologies 
The past two decades have witnessed the development of a variety of measurement tools 
and techniques for capturing diverse varieties of complex genomic and genotypic changes 
in human diseases. This was as a result of recent technological developments in the area of 
sequencing (high-throughput sequencing) that have enabled acquisition of genome-wide 
data using parallel sequencing approaches. Acquiring such data using low-throughput 
technologies/techniques, though feasible, is expensive and time consuming. Low-
throughput techniques provide pan-genomic information at the level of whole 
chromosomes and sub-chromosomal structures on the scale of megabases. With high-
throughput techniques, however, there are better resolutions, and genotype–phenotype 
correlations are now routinely established at the single-nucleotide level.  
The first draft of human genome sequence was completed in 2001 [14, 15]; the 
genome sequences of several other model organisms were determined shortly thereafter 
[16-18]. Though these breakthroughs were achieved with the traditional Sanger 
sequencing, the application to clinical diagnostics and personalized medicine was limited 
by low-throughput and high cost. The advent of high-throughput sequencing technologies 
allows sequencing of massive multiple DNA molecules in parallel at comparatively low 
cost, thus enabling hundreds of millions of DNA molecules to be sequenced 
simultaneously. 
2.1.1 High-throughput DNA microarrays 
DNA microarrays are an established high-throughput technology for measuring DNA-
protein interaction, genome-wide gene expression, and genomic variation [19-21]. The 
utility of DNA in microarray format is built on the premise that single-stranded nucleic 
acids have the ability to hybridize with high specificity to a second strand containing the 
complementary sequence, thus forming double-stranded nucleic acid molecules (Figure 1). 
This offers the advantage of studying multiple transcriptional events in a single 
experiment [22]. 
Microarrays have been applied in a broad range of applications including genotyping 
of polymorphisms and mutations [23], determining the binding sites of DNA-binding 
proteins [24], and identifying structural alterations by use of arrayed comparative genomic 
hybridization approaches [25] (Table 1). However, the most widespread use of this 
technology to date has been the analysis of gene expression [26]. Another important 
application of the DNA microarray, when used in combination with chromatin 
immunoprecipitation (ChIP) [27], is the determination of the binding sites of transcription 
factors [24, 28-35] discussed below (ChIP-chip).  
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Figure 1. DNA microarray illustrating hybridization of the target to the probe. Labeled 
DNA molecules are hybridized with probes on a microarray. (Adapted from 
Wikipedia, http://en.wikipedia.org) 
Despite the widespread applications of DNA microarray and its translation to clinical 
use as diagnostic tool, the technology suffers major limitations. Its indirect nature is a 
major drawback since the signal measured at a given position on a microarray is typically 
assumed to be proportional to the concentration of a presumed single species in solution 
that can hybridize to that location. Moreover, the technology involves a number of steps 
including chip production; probe hybridization, image quantification, normalization, and 
data interpretation. Lastly, DNA array lacks the capability to reveal unknown events since 
it always requires the use of a reference genome/sequence. 
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Table 1. Applications of DNA microarray technology 
 
Chromatin Immunoprecipitation on chip (ChIP-chip) 
ChIP-chip, a technology that combines chromatin immunoprecipitation (ChIP) with DNA 
microarray (chip), is used to investigate interactions between proteins and DNA. Unlike 
the traditional methods, ChIP-chip allows the identification of all binding sites, for DNA-
binding proteins, like transcription binding factors (TFs), on a genome-wide basis [44]. 
With the goal of locating protein-binding sites, the identified binding sites may help 
identify functional elements in the genome. Briefly, it starts by cross-linking the protein of 
interest to DNA with formaldehyde followed by fragmentation. The fragmented protein-
bound DNA is affinity purified using an antibody to the TF. The purified DNA is released 
from the TF by reverse cross-linking, amplified, labeled and hybridized on the array 
(Figure 2). In ChIP-chip, the DNA associated with a TF of interest is often compared to a 
reference sample, generally either genomic DNA or any DNA that might be 
immunoprecipitated with a negative control antibody. Furthermore, ChIP-chip entails the 
use of DNA tiling microarrays that are prepared either by deposition of PCR products or 
by oligonucleotide synthesis. Due to the fact that TFs often bind quite a distance away 
from the genes that they regulate, the design of the array and size distribution of the 
fragment length are interrelated. For example, the array must contain probes that will 
interrogate the region of DNA bound to the TF.  
Technology Purpose References 
Expression arrays Gene expression profiling (mRNA or miRNA) [26, 36] 
SNP arrays Identifying SNPs within or between populations [37, 38] 
Array CGH Assessing genome content in different cells or closely 
related organisms 
[39, 40] 
Exon arrays Detection of alternative splicing and fusion genes [41] 
DNase-chip Detection of hypersensitive sites, segments of open 
chromatin that are more readily cleaved by DNaseI 
[42] 
Methylation arrays 
(MeDIP-chip) 
Mapping and measurement of DNA methylation across the 
genome 
[38] 
ChIP-chip Genome-wide determination of protein binding sites [43] 
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Figure 2. Workflow overview of ChIP-chip experiment. (Adapted from Wikipedia, 
http://en.wikipedia.org) 
In spite of its widespread utility, several factors still pose a major limitation to its 
usability. Apart from being expensive, oligonucleotide length and array format, the 
number of replicas required obtaining the maximum of data, and specific antibodies 
requirement are major limiting factors to its widespread use in laboratories.  
Due to its major limitations, sequencing-based approach (CHIP sequencing – CHIP-
seq) [45], which does not require the use of a reference sample, is taking over. In CHIP-
seq, instead of hybridizing the resulting DNA fragments to a DNA array, the last step 
involves adding adaptors and sequencing the individual DNA fragments in parallel. In 
contrast to CHIP-chip, CHIP-seq is less expensive and does not suffer hybridization 
artifacts that may complicate interpretation of DNA microarray. 
2.1.2 Deep sequencing 
Deep sequencing constitutes the sequencing of a genomic region multiple times, up to 
thousands of repetitions using massively parallel sequencing approaches. These 
technologies enable rapid genome-wide determination of nucleotide sequences, and are 
essential in studies on genomics, epigenomics, and transcriptomics. 
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2.1.3 First generation Sanger sequencing 
The first generation sequencing technology developed by Dr Frederick Sanger and 
colleagues in 1977, Sanger sequencing, has traditionally been used to elucidate DNA 
sequence information [46]. Based on the selective incorporation of chain-terminating 
dideoxynucleotides by DNA polymerase during in vitro DNA replication, Sanger 
sequencing technology is the most widely used method for ~25 years [46, 47]. With an 
average read length of about 800 base pairs, the use of Sanger sequencing technology 
culminated in the completion of the first draft of human genome in 2001 [14, 15], and 
shortly thereafter, the genome sequences of several other model organisms [16-18]. 
However, the technology is expensive, and limited by the amount of DNA that can be 
processed at a given time and poor quality in the first 15-40 bases of the sequence due to 
primer binding and deteriorating quality of sequencing traces after 700-900 bases.    
Despite the high-throughput and low cost of NGS, Sanger sequencing retains an 
essential place in clinical genomics. Sanger sequencing still serves as an orthogonal 
method for confirming and validating sequence variants identified in clinical NGS tests. 
The Sanger approach provides the ground truth for benchmarking NGS assays, and it is 
therefore an indispensable protocol in any clinical genomics laboratory. Secondly, Sanger 
sequencing is still used for backfilling poorly covered regions in targeted NGS testing. 
2.1.4 Next generation sequencing  
To overcome the problem of low-throughput, newer sequencing technologies that can read 
the sequence of multiple DNA molecules in parallel have been developed. Collectively, 
they are called NGS [48]. In contrast to Sanger sequencing technology, NGS technologies 
have lower cost and high-throughput, as they take the advantage of massive parallel 
sequencing.    
The NGS methods otherwise referred to as second-generation approaches, represent the 
current methods for massively parallel DNA sequence analysis and sequencing. NGS 
technologies include amplification steps and utilize the sequencing-by-synthesis paradigm 
to determine the order of the DNA bases. As NGS approaches involve dispersal of target 
sequences across the surface of a two-dimensional array, followed by sequencing of those 
targets, NGS approaches have been described as cyclic array sequencing platforms [49]. 
The NGS technologies are based on immobilization of DNA samples onto a solid support, 
cyclic sequencing reaction, and imaging. Briefly, the workflow involves three major steps: 
sample/library preparation, immobilization, and sequencing using a platform of choice. 
Many commercial high-throughput sequencing platforms have been developed but this 
dissertation will focus on the sequencing chemistries developed by Illumina Corporation 
(San Diego, California, USA) (section 2.1.5), being the most widely used platforms in 
clinical genomics [50]. 
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NGS technologies have three significant improvements over the first generation 
Sanger sequencing technology [51]. Firstly, massively parallel sequencing of millions of 
colonies enabled by imaging of arrays of DNA colonies in contrast to capillaries in Sanger 
sequencing. Furthermore, the use of a common reaction volume (e.g., a glass slide) that 
distributes reagents to all colonies of the array helps to reduce cost. Lastly, amplification 
of source DNA is done by using specifically engineered DNA polymerase based 
protocols, instead of in vivo bacterial plasmid amplification used in shotgun Sanger 
sequencing. 
The advantages of NGS are currently offset by two major drawbacks: read length and 
raw accuracy, which are being overcome by technical modifications and bioinformatics 
analyses (section 2.2). Although the read lengths of the new sequencing platforms are 
shorter compared to conventional Sanger sequencing, most of the new platforms are now 
capable of producing longer read lengths. Moreover, the presence and use of reference 
genomes for aligning short reads has served as the basis for tackling this challenge though 
it represents another computational task. Moreover, the need for Sanger validation of 
genetic variants identified by clinical NGS tests highlights lower base-call accuracy of the 
new platforms. 
2.1.5 Illumina sequencing platform 
Illumina, a major provider of NGS platforms, currently produces a suite of sequencers 
(MiSeq, NextSeq 500, and the HiSeq series) optimized for a variety of throughputs and 
turnaround times. The technology was developed by Solexa and further commercialized 
by Illumina, Inc. (San Diego, CA). The technology is based on immobilizing linear 
sequencing library fragments using solid support amplification.  
Sequencing library preparation and adapter ligation 
Illumina sequencing protocol starts with random fragmentation of DNA sample, followed 
by 5’ and 3’ adapter ligation [52, 53] (Figure 3A). Adapter-ligated fragments are then size 
selected, PCR amplified and purified to improve the quality of the sequence reads.  
Bridge amplification 
The DNA library is then immobilized on a flow cell, and each single stranded fragment 
creates a ‘bridge’ structure by hybridizing with its free end to the complementary adapter 
on the surface of the support, thus forming distinct clonal clusters after several PCR cycles 
(Figure 3B). The PCR is performed in solution and involves repeated thermal cycles of 
denaturation, annealing, and extension to have an exponential amplification of DNA.  
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Figure 3. Illumina sequencing protocol. (A) Fragmentation of DNA followed by adapter 
ligation to both ends of the fragmented DNA to produce sequencing library. 
(B) The library is attached onto a solid surface of a flow cell, and “bridge” 
molecules that are subsequently amplified are formed. There is formation of a 
cluster of identical fragments that are subsequently denatured for sequencing 
primer annealing. (C) Sequencing-by-synthesis using 3′ blocked labeled 
nucleotides. (Adapted from the Genome Analyzer brochure, 
http://www.illumina.com) 
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Sequencing-by-synthesis 
Illumina sequencing-by-synthesis (SBS) technology uses a custom reversible terminator-
based method that is capable of detecting single bases, as they are incorporated into DNA 
template strands. In SBS, all four nucleotides are provided in each cycle because each 
nucleotide carries an identifying fluorescent label and an azidomethyl group in the 3’ 
carbon. The presence of all four reversible, terminator-bound dNTPs during each 
sequencing cycle helps to minimize incorporation bias and greatly reduces raw error rates 
compared to other technologies [53, 54] (Figure 3B). The sequencing occurs as single-
nucleotide addition reactions due to the existence of a blocking group at the 3’-OH 
position of the ribose sugar that prevents additional base incorporation reactions by the 
polymerase. After nucleotide incorporation, unincorporated nucleotides are washed away; 
the flow cell is imaged on both inner surfaces to identify each cluster that is reporting a 
fluorescent signal; the fluorescent groups are chemically cleaved, and the 3’-OH is 
chemically deblocked. The cycle is repeated for up to 150 times. 
2.1.6 Applications of next generation sequencing: RNA-Seq 
In recent years, NGS technology has become an essential tool for nearly all fields of 
biological research, and diverse genomic applications of NGS technology such as 
transcriptome analysis (RNA-Seq), metagenomics, or profiling of methylated DNA 
(MeDip-seq), or DNA-associated proteins (ChIP-Seq) have emerged (Table 2). Before the 
emergence of NGS, profiling of global gene expression has largely relied on microarray-
based techniques. Hybridization-based technology is restricted to known genes and has a 
limited range of quantification. In addition to its utility as a tool for measuring gene 
expression levels at higher resolution compared to microarray, NGS-based RNA-
sequencing method (RNA-seq) can reveal unknown transcripts and splicing isoforms, and 
provide quantitative measurement of alternatively spliced isoforms. RNA-seq can be used 
to measure and analyze the total RNA of a cell (transcriptome), and thereby extending the 
possibilities of transcriptome studies to the analysis of gene isoforms, translocation events, 
nucleotide variations, and post-transcriptional base modifications. In contrast to 
microarrays, RNA-seq provides absolute quantity levels; is more sensitive by comparison; 
and is not affected by on-chip sequence biases. Furthermore, RNA-seq gives additional 
information on gene expression levels and splice junction variants [55, 56]. 
Typically, RNA-seq starts with the conversion of RNA to cDNA that is more stable 
through a combination of reverse transcription and the selection process to isolate the 
RNA from the abundant ribosomal RNA (rRNA). However, the quality of input RNA is 
very important in RNA-seq preparation as it has an enormous impact on the downstream 
analysis of RNA-seq data. Moreover, RNAse enzymes used in RNA-seq are ubiquitous 
and extremely stable and can fragment simply when a divalent cation is present.  
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Although numerous variations of RNA-seq library preparations have been developed, each 
with its benefits and limitations in terms of relative costs and input requirements, library 
preparation and sequencing of cDNA follow the same sequencing procedure as DNA 
sequencing. There are three alternatives for library preparation in RNA-seq: 1) use of 
polyadenylated tail selection; 2) ribosomal depletion; and 3) use of ‘not-so-random’ 
(NSR) primers (for reverse transcription) [57-60]. The obtained fragments are then 
subjected to massively parallel sequencing with or without amplification, and the resulting 
reads are either aligned to a reference genome or reference transcriptome, or assembled de 
novo to produce a genome-scale transcription map. 
Table 2. Applications of high-throughput sequencing 
 
Abbreviations: CHIP-seq, Chromatin immunoprecipitation sequencing; Ribo-seq, 
Ribosome sequencing; GRO-seq, Global run-on sequencing; ChIA-PET, Chromatin 
interaction analysis by paired-end tag sequencing; BS-seq, Bisulfite sequencing. 
2.2 Emerging DNA sequencing technologies 
NGS technologies have enabled genomic revolution in science and medicine by their 
widespread use. Despite the widespread use of NGS technologies, however, the pace of 
technological development in the field of genome sequencing is overwhelming and new 
technological breakthroughs are emerging. The second-generation technology platforms 
include the HiSeq and MiSeq platforms manufactured by Illumina; the Roche 454 GS 
Junior platform manufactured by Roche; the SOLiD platforms manufactured by Life 
Technologies; and the Ion semiconductor platforms manufactured by Life Technologies. 
Though the technologies behind the NGS platforms differ, they all include amplification 
steps and utilize the sequencing-by-synthesis method. It is now possible to sequence 
individual DNA molecules without the need for library amplification steps using the 
emerging technologies approach. The advantages of the emerging technologies over the 
current NGS methods include: high-throughput and faster turnaround times, longer read 
Technology Purpose References 
CHIP-seq DNA–protein interactions; histone alteration [61] 
Ribo-seq Translation profiling at single codon resolution [62] 
GRO-seq Nascent RNA quantification [63] 
ChIA-PET Chromatin conformation related to a protein of interest [64] 
BS-seq Genome methylation [65] 
Hi-C DNA–DNA interactions (chromatin conformation) [66] 
RNA-seq Gene expression profiling, transcript analysis [67] 
Metagenomics Identification of microbial species in the environment [68] 
DNA-seq De novo assembly, genetic variation profiling [14, 15, 69] 
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lengths, higher consensus accuracy, avoidance of the artifactual DNA mutations and 
strand biases introduced by even limited cycles of PCR, and analysis of smaller quantities 
of nucleic acids. 
2.2.1 Third generation sequencing approaches 
The third-generation sequencing platforms offer the possibility to sequence individual 
DNA molecules without the need for a template amplification step. However, they still use 
sequencing-by-synthesis method. The current third-generation sequencing platforms 
include the PacBioRS by Pacific Biosciences and the Heliscope Sequencer by Helicos 
BioSciences [70-72]. 
Single-molecule real-time (SMRT) DNA sequencing 
The SMRT technology is a product of three major technological breakthroughs: the 
SMRT cell which makes it possible to observe incorporation of individual nucleic acids in 
real time; a novel detection platform that enables single-molecule detection, and the use of 
phospholinked nucleotides, which enables long read lengths. The technology makes use of 
sequencing-chip containing thousands of zero-mode wave-guides (ZMWs). In SMRT 
approach, sequencing of a single DNA template molecule is carried out by a single DNA 
polymerase molecule attached to the bottom of each of the ZMWs [73, 74]. However, 
SMRT approach still involves sequencing-by-synthesis and utilizes deoxynucleotides 
(dNTPs) that are fluorescently labeled. Besides its high-throughput and faster turnaround 
time, the SMRT approach produces long read lengths that make de novo assembly of 
larger contigs and ultimately genomes much more computationally feasible without the 
subcloning and mapping approach used in the original human genome project. 
Furthermore, SMRT sequencing approach offers the possibility of direct identification of 
epigenetic modifications [75]. 
2.2.2 Fourth generation sequencing approaches 
The fourth-generation sequencing approaches, though still years away from widespread 
clinical use, utilize different principles of chemistry and physics to produce DNA 
sequence as against the sequencing-by-synthesis principle used by third-generation 
sequencing technologies. Based on nanopore technologies, the forth-generation 
sequencing platforms permit sequence analysis of single DNA molecules, do not involve 
prior amplification steps, and the sequencing step is performed without DNA synthesis 
[76]. 
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Nanopore sequencing 
In contrast to other DNA sequencing methods based on sequencing-by-synthesis, 
nanopore-based sequencing relies on variations in electrical currents as a result of 
translocation of individual DNA molecules through artificial nanopores that perforate a 
membrane. This theory has been validated in a number of studies that have shown that 
modulations of ionic current can be measured as RNA or DNA strands translocate through 
the pore [77, 78]. There is a wide interest in nanopore sequencing as it is expected to offer 
solutions to the limitation of NGS technology by producing extremely long read lengths 
(up to 50,000 bp).  
2.3 Clinical genome sequencing 
Technological advances have revolutionized genome sequencing, yielding high profile 
clinical research studies. However, translating technological breakthroughs into 
widespread clinical use is challenging. Implementing clinical genome sequencing is labor 
intensive and requires bioinformatics expertise together with robust laboratory process. 
Aside from being high-throughput, NGS has a wide range of qualitative and quantitative 
applications including exome sequencing, RNA-seq, CHIP-seq, metagenomics, and WGS 
(Table 2). These applications can help to unravel diverse genomic alterations including 
single nucleotide variants (SNVs), insertions and deletions (INDELs), copy number 
variations (CNVs) and gross structural variants (SVs) that may be responsible for the 
genetic basis of disease. These applications have been modified and adapted in different 
ways for clinical diagnostics. 
2.3.1 Clinical whole genome sequencing 
WGS is a non-selective method in which the entire genomic content is sequenced. The 
decreasing cost of sequencing has facilitated an increasing application of WGS in clinical 
medicine. WGS has been used to reveal the genetic basis of rare familial diseases [79-81], 
explain novel disease biology [82, 83], and aid clinical diagnosis [84-86]. Although the 
cost of WGS has drastically decreased, several factors have limited its clinical use. First, 
WGS is limited in clinical use by lack of understanding of the functional clinical role of 
variants identified in most genes, as well as nearly all noncoding regions. Another factor 
limiting its use among others is bioinformatics constraints as a result of the huge amount 
of data being generated.  
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2.3.2 Targeted next generation sequencing 
In order to tackle the inherent limitations of WGS, targeted NGS approaches that aim at 
evaluating only a selected portion of the genome, ranging from WES to candidate genes 
sequencing, have been developed [87-93]. In brief, there are two approaches to target 
enrichment: hybrid capture-based and amplification-based, both of which can be used for 
a diverse range of applications on several different sequencing platforms. 
2.3.3 Targeted hybrid capture NGS 
Targeted hybridization methods rely on the principle of complementary base pairing of 
nucleotides to capture target regions, and utilize DNA or RNA probes. The success of 
hybrid capture-based NGS is affected by a range of factors including: efficiency of probe 
design, on-target coverage, coverage uniformity, analytical specificity and sensitivity, 
input DNA quantity requirement, library complexity, scalability, overall cost, 
reproducibility, and ease of use. In addition, base composition and sequence homology 
greatly influence capture efficiency and coverage of the target region of interest (ROI). 
In general, there are three main hybrid capture-based target enrichment strategies: 
solid-phase hybrid capture, in-solution hybrid capture, and molecular inversion probes that 
are available. Each of the strategies has its own drawbacks and strengths. The solid-phase 
hybrid methods for NGS arose from microarray technologies, and capture platforms 
utilize high-density clusters of unique oligonucleotides bound to a solid substrate. 
Whereas solid-phase hybrid capture uses an excess of DNA library template molecules 
over probes, in-solution capture employs an excess of probes over DNA library molecules. 
This helps in driving the hybridization reaction to completion faster with smaller 
quantities of the DNA library. The molecular inversion probes on the other hand combines 
either array-based or solution-phase target capture enrichment with amplification [94, 95].  
2.3.4 Amplification-based NGS 
In contrast to hybridization-based capture approach, amplification-based NGS utilizes 
polymerase chain reaction (PCR) amplification for enrichment of genomic regions of 
interest. For a successful and high-quality capture, several factors and steps are required. 
These include adequate sample, quality and quantity of isolated DNA/RNA, selection of 
appropriate genetic targets and careful primer design, optimization of PCR conditions to 
yield specific products, efficient library preparation, and accurate sequencing. 
Amplification-based NGS, in contrast to hybrid capture, provides a uniform coverage of 
the amplified region, and is less sensitive to base composition.  
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2.3.5 Application of targeted NGS – OS-Seq 
OS-Seq is a targeted resequencing approach whereby the surface of a sequencing flow cell 
is modified to capture specific genomic regions of interest from a sample before 
sequencing. OS-seq method uses an Illumina flow cell that serves as both a capture device 
and as its normal support device in the sequencing workflow. Unlike traditional bait 
hybridization strategies for target enrichments, OS-seq relies on hybridization of a 
genomic library to a target-specific primer probe that is located on the surface of an 
Illumina flow cell. A subsequent polymerase extension extends the specific genomic target 
using the primer probe. All steps of target selection occur on the same solid phase support 
that mediates the sequencing (Figure 4). 
2.3.6 High-throughput bioinformatics 
Advances in genome technology coupled with rapid decline of cost per base pair have 
enabled widespread use of NGS. The current bottleneck is not the sequencing of the DNA 
itself but lies in data management and the sophisticated computational analysis of the huge 
data generated [96]. Despite this bottleneck, several softwares and tools have been 
developed for the analysis and identification of genomic aberrations including single 
nucleotide variants (SNVs), insertions and deletions (INDELs), translocation, and copy 
number variations from NGS data.  
Briefly, NGS data analysis generally starts with quality assessment of the raw reads 
often followed by correction, trimming and sometimes removal of low quality reads. This 
step is very crucial as raw sequence data from different sequencing platforms are 
compromised by sequence artifacts such as base calling errors, INDELs, poor quality 
reads and adaptor contamination [97]. Commonly used tools for NGS data quality 
assessment include FastQC [98] and PRINSEQ [99].  
Preprocessed reads that passed quality assessment are usually aligned to a reference 
genome (or assembled de novo depending on the research goal). Among the commonly 
used alignment tools are BWA [100], Bowtie [101], MAQ [102], mrFAST [103], and 
SOAP [104] to mention but a few. Alignment stage is followed by another crucial step in 
NGS data analysis, identification of variants. Identified variants are further annotated to 
determine their functional effect. 
Single nucleotide variants (SNVs) are the most common type of nucleotide change 
although coding DNA and associated regulatory sequences are under selection pressure, 
which has reduced the rate of single base pair substitutions. There are several tools that 
have been designed for the identification of SNVs from NGS data using different 
algorithms. Regardless of the tool, SNV identification from NGS data relies on several 
data features and quality metrics including the base quality, mapping quality, strand bias, 
depth of coverage, and properties of the reads aligned to a candidate SNV position. 
Another type of genomic aberration is INDEL characterized by insertion, deletion or 
insertion and deletion of nucleotide <1kb into genomic DNA. INDELs are known to occur 
commonly in repetitive part of the genome. This makes their identification and annotation 
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challenging, and consequently, specific tools are required for INDELs detection. 
Moreover, most analysis tools are generally optimized for one class of mutation; hence, 
tools optimized for SNVs detection are not optimized for INDELs detection.   
 
 
 
Figure 4. OS-Seq target capture workflow. Step 1, primer probes are created by using 
target-specific oligonucleotides to modify flow cell primers. Hybridized 
oligonucleotides serve as template for DNA polymerase. After extension of D 
primers and denaturation, target-specific primer probes are randomly 
immobilized on the flow. Step 2, primer probes are used to capture genomic 
targets in a single-adaptor library during a high-heat hybridization step to 
their complementary primer probes. Captured single-adaptor library 
fragments serve as template for DNA polymerase, followed by extension of 
primer probes. Templates DNA are released from immobilized targets by 
denaturation. Step 3, immobilized captured targets are modified to be 
compatible for DNA sequencing. DNA polymerase is used to extend the 3´ 
ends of immobilized targets and C primers, and molecules capable of 
undergoing bridge PCR are produced. (Adapted from Myllykangas et al. [13])     
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2.4 Angiogenesis 
Angiogenesis, growth of new blood vessels from the pre-existing vasculature, could be 
divided into two types: physiological and pathological. While the latter may contribute to 
many diseases, such as cardiovascular disease, cancer, and inflammation, the former is a 
basic physiological process important for organ development, reproduction, wound 
healing and tissue maintenance. Pathological angiogenesis, however, can be insufficient, 
which leads to heart disease and delayed wound healing, or excessive, which paves the 
way for aberrant tissue growth [105]. 
This complex blood vessel formation process involves interplay between a variety of 
angiogenic growth factors which when perturbed results in various pathophysiological 
conditions and diseases including cancer, cardiopulmonary disorders, and diabetes [106-
111].  
Proliferation and migration of endothelial cells (EC), which form the primitive tools 
that become blood vessels, is the hallmark and an essential component of angiogenesis. 
The process is directionally regulated by chemotactic, haptotactic, and mechanotactic 
stimuli, and involves degradation of the extracellular matrix as well as activation of 
several signaling pathways that modulate cytoskeletal remodeling [108, 112, 113]. 
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription 
factors (TFs) nuclear hormone receptor superfamily, comprising of three subtypes: 
PPARα, PPARγ, and PPARβ/δ, best known for their role in lipid and energy homeostasis, 
and metabolic function [114-116]. The PPARs are important regulators of proliferation, 
development, and inflammation [117]. Although PPARs exhibit tissue-specific pattern of 
expression and differ in the spectrum of their activity, all PPARs are expressed in ECs. 
The angiogenic profile of specific PPARs is controversial. This is as a result of their 
differential effects in various tissues and pathological states [116, 118]. Despite this, 
PPARs are generally known to play important roles in EC homeostasis [118-121]. 
Activation of PPARβ/δ has been shown to promote angiogenesis in both in vitro and in 
vivo models by inhibiting the proliferation of endothelial cells though the mechanism 
remains unclear [122-124]. PPARγ, on the other hand, can either inhibit or promote 
angiogenesis in both in vitro and in vivo models depending on the context [119-121, 125-
127]. 
2.5 Etiology and genetics of dilated cardiomyopathy 
Dilated cardiomyopathy (DCM) is a disease of the myocardium characterized by 
enlargement of the left ventricle or both ventricles of the heart, accompanied by 
diminished myocardial contraction. According to the position statement of the European 
Society of Cardiology (ESC), DCM is a diagnosis of exclusion, and requires an active 
elimination of abnormal loading conditions (systemic hypertension, valve disease) and 
significant coronary artery disease capable of causing global systolic impairment [128]. 
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DCM is the most prevalent indication for heart transplantation and a relatively common 
cause of heart failure and sudden cardiac death, with a prevalence of at least 1:2500 [6-8]. 
The etiology of DCM is highly heterogeneous. Underlying etiologies vary from 
genetic, infectious, autoimmune and toxic causes. Based on etiology, ESC classified DCM 
into two classes: familial (genetic) and non-familial forms [128]. Non-familial causes for 
DCM include active myocarditis, metabolic diseases (diabetes, thyroid disorders and 
pheochromocytoma), toxics exposures (alcohol, anthracyclines, lithium, cocaine), storage 
diseases (hemochromatosis) and systemic diseases (sarcoidosis and connective tissue 
diseases) [129-131].  
Inherited cardiomyopathies are genetically heterogeneous and the genetic 
heterogeneity is more pronounced in DCM than in other cardiomyopathies, with currently 
more than 50 genes implicated, most contributing only a modest fraction to the pathogenic 
variations in DCM patients [132, 133]. Genetic characterization of DCM is challenged by 
our incomplete knowledge of the genes involved in the etiology of the disease together 
with variation in population structure and genetics. As most DCM causing variations are 
rare and often ”private” to families, genetic characterization of DCM becomes more 
challenging in a bottle-necked population such as the Finnish population, characterized by 
smaller spectrum of rare variation in contrast to out-bred populations. Furthermore, 
significant clinical overlap between DCM and other cardiomyopathies (hypertrophic 
cardiomyopathy [HCM], arrhythmogenic right ventricular cardiomyopathy [ARVC]) can 
potentially lead to diagnostic uncertainty in some cases [134-138].  
2.5.1 Inherited origin underlying dilated cardiomyopathy 
When DCM occurs in the absence of an identifiable cause, the disease is referred to as 
idiopathic DCM (iDCM). Among patients with iDCM, approximately 30% have affected 
first-degree family members, implying a genetic etiology [139-142]. As disease 
expression in family members of clinically apparent probands is often subclinical, the 
prevalence of familial DCM (fDCM) by history alone is probably underestimated. 
Furthermore, age-dependent penetrance, non-penetrance and occurrence of de novo 
mutations may contribute to underestimation of the prevalence of familial DCM. While 
most DCM-causing mutations are often inherited in an autosomal dominant fashion, 
autosomal recessive, X-linked, and mitochondrial [142] inheritance account for a minority 
of fDCM cases. The penetrance of fDCM is age- and gene-dependent, with disease 
developing in childhood, adolescence, and middle age, but rarely in the elderly [143]. In 
fDCM, although recent studies have reported recurrent variants in multiple families, 
nearly all disease-causing gene mutations are unique to that family (‘private’ mutations) 
[144, 145]. Familial DCM exhibits profound genetic heterogeneity and DCM-causing 
mutations have been identified in genes encoding the components of the sarcomere, 
cytoskeleton, nuclear lamina, calcium-handling genes and mitochondria, as well as those 
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encoding proteins of the dystrophin-associated complex including – sarcoglycan (SGCD) 
and dystrophin (DMD) (Table 3). 
2.5.2 Genetic overlap with other forms of cardiomyopathy 
Genetic studies on different cardiomyopathies have revealed significant overlap between 
genotypes and phenotypes as mutations in one gene can manifest as various forms of 
cardiomyopathy [146]. During the early days when the genetic causes of cardiomyopathies 
were first identified, it was believed that DCM and HCM were caused by cytoskeleton and 
sarcomere dysfunction respectively, and the genes encoding desmosome proteins were 
associated with ARVC. However, more extensive surveys have revealed significant 
heterogeneity; genes causing HCM and ARVC have been reported to cause DCM. This 
implies that genetic mutation in a gene can cause different cardiomyopathy phenotype 
[147]. Although rare, the same mutation in the same gene has also been reported to be 
associated with different cardiomyopathy subgroups, even within a single family [148]. 
2.5.3 Modifiers of dilated cardiomyopathy 
DCM demonstrates variable penetrance even within the same family. Furthermore, DCM 
is characterized by highly variable expressivity. Variable penetrance and expressivity 
imply that factors other than single pathogenic mutation influence the phenotype. These 
may include genetic, epigenetic and environmental factors [149-152]. The influence of 
epigenetics and environment on DCM is actively being studied, and it is expected that 
technological advances in the area of NGS will go a long way in shedding more light in 
this research area. The technology has been used in identifying compound heterozygosity 
(≥2 mutations in the same gene) and digenic/oligogenic heterozygosity (≥2 mutations in 
different genes) in arrhythmogenic cardiomyopathy characterized with low penetrance 
[153].  
2.5.4 Genetic testing in dilated cardiomyopathy 
DCM is often due to an underlying genetic change in more than 50 genes (Table 3). 
Detection of a disease-causing mutation in any of these genes therefore allows diagnosis 
of DCM. In addition, genetic testing can also detect a predisposition for DCM in 
individuals who do not yet have symptoms. Furthermore, the genotype sometimes can 
influence patient care: LMNA mutation carriers may be more prone to conduction system 
disease. In the event of identifying a pathogenic variant in a proband, genetic testing can 
allow for informed evaluation of family members implications for medical follow-up for a 
proband’s siblings, children, and parents.  
As DCM is characterized by profound locus and allelic heterogeneity, genetic testing 
for DCM is now only becoming more widely used in clinical practice. Until the advent of 
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Table 3. Genes associated with non-syndromic familial dilated cardiomyopathy 
 
Abbreviations: ARVC, arrhythmogenic right ventricular cardiomyopathy; HCM, 
hypertrophic cardiomyopathy. 
Gene Encoded protein OMIM Estimated 
detection rate in 
DCM population
Other associated 
cardiomyopathy
References
ACTC1 α-Cardiac actin 102540 <1% HCM [154, 155]
ACTN2 α-Actinin-2 102573 <1% HCM [156]
ANKRD1 Ankyrin repeat domain-containing protein 1 609599 2% HCM [157]
CSRP3 Cysteine and glycine-rich protein 3 (cardiac 
LIM protein)
600824 <1% HCM [158, 159]
MYBPC3 Cardiac-type myosin-binding protein C 600958 1-4% HCM [160, 161]
MYH6 Myosin-6 (α-myosin heavy chain) 160710 3% HCM [160, 162]
MYH7 Myosin-7 (β-myosin heavy chain) 160760 4-7% HCM [144, 158, 161, 163]
MYPN Myopalladin 608517 2-4% HCM [164]
TCAP Telethonin (titin cap protein) 604488 <1% HCM [158, 165]
TNNC1 Cardiac muscle troponin C 191040 1% HCM [166, 167]
TNNI3 Cardiac muscle troponin I 191044 <1% HCM [168, 169]
TNNT2 Cardiac muscle troponin T 191045 1-5% HCM [170, 171]
TMP1 α1-Tropomyosin 191010 2% HCM [172, 173]
TTN Titin 188840 21% HCM [9, 174, 175]
LMNA Lamin-A/C 150330 5-9% ARVC [176-188]
TMPO Thymopoietin 188380 <1% [189]
GATAD1 GATA zinc finger domain-containing protein 1 614518 - - [190]
DSC2 Desmocollin-2 610476 - - [191]
DSG2 Desmoglein-2 125671 <1% ARVC [191]
DSP Desmoplakin 125647 2% ARVC [191]
JUP Junction plakoglobin 173325 2% ARVC [192, 193]
PKP2 Plakophilin2 602861 3% ARVC [194]
FHL2 Four and a half LIM domains 2 602633 - -
NEXN Nexilin 613121 1% HCM
DES Desmin 125660 1-2% ARVC [195, 196]
DMD Dystrophin 300377 - - [197, 198]
ILK Integrin-linked protein kinase 602366 <1% [199]
LAMA4 Laminin subunit α4 600133 1% [199]
LDB3 LIM domain-binding protein 3 (protein cypher, 
ZASP)
605906 <1% HCM [159, 200]
PDLIM3 PDZ and LIM domain protein 3 605889 <1% [201]
SGCD δ-Sarcoglycan 601411 <1% - [202-204]
VCL Vinculin 193065 <1% HCM [163, 205]
ABCC9 ATP-binding cassette subfamily C member 9 
(sulfonylurea receptor 2)
601439 <1% [172]
SCN5A Sodium channel protein type 5 subunit α 600163 2-3% ARVC [158, 206, 207]
PLN Phospholamban 172405 <1% HCM, ARVC [208-211]
PSEN1 Presinillin-1 104311 <1% - [212]
PSEN2 Presinillin-2 600759 <1% - [212]
DOLK Dolichol kinase 610768 - -
RBM20 RNA-binding protein 20 613171 2% - [145, 213]
TAZ Tafazzin 302060 - - [214, 215]
BAG3 BAG family molecular chaperone regulator 3 603883 - [216, 217]
CRYAB α-Crystalin B chain 123590 <1% - [218]
EYA4 Eyes absent homolog 4 605362 - - [219]
RYR2 Ryanodine receptor 2 180902 - -
Sarcomeric
Nuclear envelop
Desmosomal
Cytoskeletal
Ion channel
Calcium handling protein
Endoplasmic reticulum
RNA binding
Mitochondrial
Others
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NGS, wide scale profiling of large DCM cohort has been impossible, as such studies have 
been limited to and by the candidate gene and/or exon approach. With NGS, it is now 
possible to screen large number of genes to enable effective genetic testing. However, 
testing many DCM-associated genes raises several issues of variant interpretation and 
assessment. The current yield of genetic testing in DCM is about ~30%, and most DCM 
genes contribute only a small percentage of all pathogenic variants suggesting that there 
are additional genes or noncoding variation yet to be discovered [158, 166, 220, 221].  
2.5.5 Titin mutations and dilated cardiomyopathy 
TTN encodes titin, the largest and the third most abundant striated-muscle protein. It spans 
half of the sarcomere from Z-line to M-line [222, 223]. Titin is known to play a key role in 
muscle assembly [224, 225], force transmission [226, 227], and maintenance of resting 
tension [228, 229]. Structurally, TTN is organized into four functionally distinct parts: the 
amino-terminal Z-line; the I-band and A-band regions, which constitute the majority of the 
protein; and the carboxyl-terminal M-line extremity. The Z-line of TTN contains multiple 
immunoglobulin (Ig)-like domains, and anchors TTN to the sarcomeric Z-disk through 
binding to multiple proteins. The highly variable I-band is made up of repetitive domains 
that act as a molecular spring, providing TTN with its elasticity and enabling this giant 
protein to maintain its Z- and M-line connections during muscle elongation and 
contraction [230, 231]. The variability in the I-band region accounts for the differences in 
elasticity of different titin isoforms. The clinically relevant A-band of TTN binds to the 
thick filament, where it may regulate filament length and assembly, and is thought to be 
critical for biomechanical sensing and signaling. The M-line is known to function in 
sarcomere assembly through the titin kinase domain, which may have a role in cardiac 
signal transduction [232].  
Truncating TTN mutations, especially in A-band region, represent the most common 
cause of dilated cardiomyopathy (DCM). Recently, Herman et al. [9] estimated TTN 
truncating variants (TTNtv) - nonsense, frameshift and consensus splice site, to be 
responsible for approximately 25% of familial cases of idiopathic dilated DCM and 18% 
of sporadic cases in a large cohort of subjects. Prior to the era of NGS, only a handful of 
TTN mutations have been found to associate with cardiomyopathies [175, 232-238]. This 
has largely been due to the difficulty to sequence large TTN gene with its ~363 exons. 
Consequently, TTN mutation frequency and therefore clinical impact were unknown. Due 
to increased use of NGS in the last few years, TTN has emerged as a major gene in human-
inherited disease, and there has been a surge in the number of TTN mutations identified 
both in health and disease.  
Despite of this, clinical interpretation of TTNtv identified has been challenged by the 
existing inaccurate variant assessment strategy as a result of the uncertainty in the true 
frequency of TTNtv across the general population. Knowledge of the true frequency, 
location and the complete map of TTNtv in the population are therefore needed in order to 
help in the assessment of TTNtv identified in clinics.  
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3. Aims of the study 
The overall aim of the study was to utilize a variety of bioinformatics tools and strategies 
to tackle biological and clinical questions in the field of cardiovascular diseases. This 
dissertation project focuses on addressing a diverse set of analytical and interpretative 
challenges that have been emerging from the advances in the high-throughput sequencing 
technology. This general aim can be broken down to four more specific aims that would 
together achieve the overall goal of the project: 
 
1. Dysfunctional endothelium is a hallmark of several cardiovascular diseases. My first 
aim was to utilize RNA-Seq and bioinformatics strategies to quantify and reveal global 
gene expression changes associated with loss of PPARγ in human pulmonary 
microvascular endothelial cells (PMVEC) in a bid to unravel how PPARγ modulates 
endothelial homeostasis, regulates angiogenic response, and could contribute to the 
pathobiology of human cardiovascular diseases.  
 
2. To evaluate, for the first time, the genetic profile of Finnish patients with DCM and to 
establish potential genotype-phenotype correlations. The goal was to evaluate the 
diagnostic efficacy of high-quality sequencing platform in familial and sporadic DCM. 
For this study, I developed a bioinformatics pipeline for analyzing high-throughput 
data from a novel sequencing technology (OS-Seq – Oligonucleotide Selective 
Targeted Sequencing). 
 
3. Truncating TTN variants are the major cause of DCM. Interpretation of these variants 
has been challenging as the prevalence among healthy populations has been suggested 
previously to be relatively high. My aim was to utilize the largest available ExAC 
reference population, with over 60,000 individuals and improved data quality, to 
evaluate the prevalence and features of truncating TTN variants in the reference 
population, and develop variant interpretation and prioritization strategy to improve 
clinical interpretation of truncating TTN variants. 
 
4. To assess accumulated truncating TTN variants identified in DCM patients and 
reference population using the variant assessment and prioritization strategy developed 
previously. The aim was to further evaluate the role and relevance of truncating TTN 
variants in the pathogenesis of DCM, and provide insights that may improve clinical 
interpretation of genetic test results. 
 
 
 
 
 
32 
4. Materials and methods 
4.1 Approval of ethics committee 
Ethical committee of the University of Helsinki approved the study, and written informed 
consent was obtained from all patients that participated in the study.   
4.2 Study subjects and materials 
4.2.1 Cell culture (study I) 
PMVECs (human EC-L, Sciencell Research Laboratories, Carlsbad, CA, USA) used in 
study I were grown on commercial EGM-2 media (Lonza Clonetics, Fisher Scientific Oy, 
Vantaa, Finland) in gelatin-coated dishes. All cells were used between passages 4 -10. 
4.2.2 Subjects in study II 
Study II cohorts comprised of 145 unrelated DCM patients (63 familial and 82 sporadic) 
of Finnish origin (Finn-DCM) recruited between 1999 and 2013 from Helsinki University 
Hospital. All patients fulfilled the commonly used diagnostic criteria for DCM: left 
ventricular (LV) ejection fraction (LVEF) < 45%, LV end-diastolic diameter (LVEDD) > 
27mm/m2 [239]. All patients having secondary causes for DCM were excluded from the 
study. 
4.2.3 Subjects in study III 
The individuals in study III represent the reference populations from three major projects 
with publicly available datasets: the 1000 Genomes (1KG) Project with over 2500 
individuals; Exome Sequencing Project (ESP) with over 6500 individuals; and Exome 
Aggregation Consortium (ExAC) with over 60000 individuals [69, 240, 241].  
4.2.4 Subjects in study IV 
The subjects in this study represent an aggregation of over 1700 DCM patients from four 
major studies:  Herman et al.[9]; Haas et al.[242]; Roberts et al.[243]; and Akinrinade et 
al.[244], herewith referred to as cohorts: A, B, C, and D respectively. Detail information 
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about the cohorts are as previously reported [9, 242, 243, 245]. Cohort D represents the 
Finn-DCM cohorts mentioned above. 
4.3 RNA extraction and sequencing (I) 
PMVECs were transfected with non-target siRNAs (control) and PPARγ siRNAs, and 
harvested 48h after transfections. Samples were purified using NucleoSpin® RNA Clean 
up-kit (Macherey-Nagel) according to manufacturer’s instruction. RNA samples were 
prepared for Illumina sequencing following the instruction provided by New England 
BioLabs® Inc (NEB BioLabs, Ipswitch, MA, USA). Total RNA of 1-5 μg was used as 
starting material. Isolation of poly(A)+ RNA transcripts from total RNA for RNA library 
preparation and sequencing was done using the NEBNext Oligo d(T)25 magnetic beads 
(NEB BioLabs). Isolated samples were fragmented and cleaned up with RNeasy MinElute 
Clean-up Kit (Qiagen Nordic, Helsinki, Finland) following manufacturers´ instructions.  
Synthesis of double-stranded cDNA and purification were done with 1.8X Agencourt 
AMPure XP Beads before sequencing. RNA sequencing was done in collaboration with 
Institute of Molecular Medicine Finland (FIMM, Helsinki, Finland) using the Illumina 
HighSeq® 2000 System (Illumina, San Diego, CA) with pair-end cluster (100 bp) in one 
lane. 
4.3.1 Quality control and data preprocessing (I, II) 
The quality of raw sequence data in studies I and II were assessed using FastQC [98]. 
Based on the QC results of the raw data, appropriate data preprocessing including base 
trimming, read filtering, or adaptor clipping were done using Trimmomatic in paired-end 
mode [246]. Trimmomatic is a java application that provides useful functions for handling 
paired-end reads. High quality reads were mapped to human genome reference sequence 
build (hg19) using Burrows-Wheeler Algorithm (BWA) (studies I & II) [100] and TopHat 
(study II) [247]. 
4.3.2 RNA-Seq data analysis 
mRNAs abundance for all annotated genes from the ENSEMBL v72 annotation of the 
human genome (hg19) was calculated using an in-house R script. The R script was used to 
count the number of reads that mapped to each annotated gene, allowing, in some cases, 
for reads to partially overlap with the exons and still be counted for that gene (i.e. union). 
The counts for all the samples were collated into one file and any gene with fewer than 
five reads in all samples was excluded from the subsequent statistical analysis of 
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differential gene expression. The workflow for RNA-Seq data analysis is shown in Figure 
5.  
 
 
Figure 5. Simplified representation of implemented RNA-Seq data analysis workflow. 
4.3.3 Differential gene expression analysis 
In order to find differentially expressed genes (DEG) between PPARγ deficient human 
PMVEC and the contol PMVEC, three different methods were used: edgeR, DESeq and 
baySeq bioconductor packages and applying packages built-in procedures for library 
normalization and estimation of variance [248-250]. Benjamini and Hochberg (BH) 
method , implemented in R (version 3.0.0) was used to correct for multiple testing in each 
analysis [251]. Genes detected by at least two out of three methods with P-value<0.05 and 
FDR<0.01 were regarded as being significantly differentially expressed (SDE). All genes 
that were found to be significantly differentially expressed between the two experimental 
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conditions were retained for further analysis. Data is available in the GEO database under 
the accession number GSE62982. 
4.3.4 Pathway enrichment and gene ontology analyses of DEG 
Gene set enrichment analysis of the differentially expressed genes was performed using 
GOstats bioconductor package [252]. Hypergeometric tests with the Benjamini-Hochberg 
false discovery rate (FDR) were performed to adjust the P-value. 
4.4 Chromatin immunoprecipitation (I) 
Chromatin immunoprecipitation (ChIP) assay was done using chromatin 
immunoprecipitation (ChIP) assay kit (Millipore) following the instructions of the 
manufacturer. Cross-linking was done with 1% formaldehyde. After incubating for 10 
minutes at 37 °C, cells were washed with 1XPBS containing protease inhibitors. DNA was 
fragmented using Covaris-ultrasonicator with the sonication program provided by the 
manufacturer for 500 bp DNA shearing. Reduction of nonspecific background was done 
by pre-clearing the diluted cell supernatant with protein A Agarose/Salmon Sperm DNA 
(Millipore). Agarose was pelleted by centrifugation, and the supernatant was collected. 
Immunoprecipitating PPARγ-antibody was added to a fraction of the supernatant and 
incubated over night. No-antibody immunoprecipitation was performed for a negative 
control by incubating the supernatant fraction with Protein A Agarose/Salmon Sperm 
DNA. Pelleted complex was washed for 5 minutes once with Low Salt Immune Complex 
Wash Buffer, once with High Salt Immune Complex Salt Wash Buffer (Millipore), once 
with LiCl Immune Complex Wash Buffer and twice with TE Buffer. Elution was done in 
1% SDS and 0.1 M NaHCO3 buffer before reverse cross-linking of the eluate by adding 5 
M NaCl and heating at 65 °C for 4 hours. DNA samples were further purified by adding 
0.5 M EDTA, 1 M Tris-HCl, and 20 mg/ml Proteinase K and incubated for 1 hour at 45 
°C. DNA recovery was done by phenol/chloroform extraction and ethanol precipitation. 
4.4.1 In silico analysis of transcription factor binding sites 
Transcription factor binding site (TFBS) enrichment analyses was performed on vertebrate 
transcription factors using the oPOSSUM single site analysis tool [253] with threshold 
criteria of z-score ≥ 10 and a Fisher score ≤ 0.01. Putative promoter regions (intervals 
within 1.5 Kb of the transcription start site) were identified using data available on the 
UCSC genome browser (http://genome.ucsc.edu/). TFBS near the transcription start sites 
were identified from putative promoter regions via the Jaspar motif analysis tool 
(http://jaspar.genereg.net). 
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4.4.2 Identification of transcription factors downstream of PPARγ  
A combination of in silico promoter analysis and bioinformatics approach was used to 
search for potential transcription factor binding sites on target promoters. To identify 
transcription factor that are potential regulators of specific target genes and downstream 
targets of PPARγ, the obtained profile was compared with the previous results from ChIP-
chip analysis of PPARγ target promoters in pulmonary ECs [29] and the RNA-Sequencing 
results associated with loss of PPARγ in pulmonary ECs.  
4.5 DCM patients samples and DNA extraction (II) 
Blood samples from 145 Finnish DCM patients (Finn-DCM) were selected with the 
written informed consent from all participants for genetic analysis. DNA was extracted 
with the Qiagen DNeasy Blood and Tissue kit (Qiagen Sciences, Germantown, MD, 
USA), and subjected to targeted sequencing. 
4.5.1 Oligonucleotide-selective targeted sequencing (OS-Seq) 
Extracted genomic DNA from blood samples obtained from all subjects in study II were 
sequenced using Oligonucleotide-selective sequencing (OS-Seq). In OS-Seq, 
oligonucleotide-functionalized Illumina flow cells were used for both capture and 
sequencing of DNA. Performance, specificity and sensitivity of the method has been 
discussed elsewhere [13]. A 101-gene OS-Seq based targeted sequencing panel (Pan 
Cardiomyopathy Panel, Blueprint Genetics v.1.0) was used. Target DNA capture and 
sequencing were automated using the MiSeq sequencer. The panel was designed to screen 
2515 consensus coding sequence (CCDS) regions and splice junctions of 51 known genes 
and 50 candidate genes associated with dilated cardiomyopathy and implicated in other 
inherited cardiomyopathies respectively, based on Online Inheritance in Man (OMIM) 
database annotations and literature [254, 255]. 
4.5.2 OS-Seq data analysis 
Picard tool was used to mark and/or remove PCR duplicates from aligned reads, and base 
quality score recalibration (BQSR) and insertion-deletion (INDEL) realignment around 
targeted region were implemented before variant identification using GATK  (v.3.1-1) 
[256].  
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4.5.3 Variant calling and annotation 
Following GATK best practices recommendation, SNP and INDEL discovery and 
genotyping were implemented in a multi-sample mode, using standard hard filtering 
parameters (Phred-scaled genotype quality score threshold of 30). Identified variants were 
filtered for mapping and call/variant qualities, annotated using Ensembl’s Variant Effect 
Predictor tool (VEP) [257], and pathogenicity of nonsynonymous missense variants was 
predicted in silico using two ensemble scores from the database of human non-
synonymous SNPs and their functional predictions (dbNSFP) – MetaSVM and MetaLR – 
which incorporate 10 scores (SIFT, PolyPhen-2 HDIV, PolyPhen-2 HVAR, GERP++, 
MutationTaster, Mutation Assessor, FATHMM, LRT, SiPhy, PhyloP), and the maximum 
frequency observed in the 1000 genomes populations [258]. 
4.5.4 Variant filtering and prioritization strategy 
Variant filtering and prioritization strategies developed and implemented in this study are 
described in detail in original publications II and IV, and Figure 6. Furthermore, variants 
passing the filtering criteria were compared with the variants reported in matched 
reference population – Finnish SISu (Sequencing Initiative Suomi Project) reference 
cohorts. After removing benign polymorphisms with respect to the matched reference 
population, all rare variants were classified as ‘pathogenic’ (P), ‘likely pathogenic’ (LP), 
‘variants of unknown significance’ (VUS), ‘likely benign’ (LB), and ‘benign’ (B) 
following ACMG recommendations [259]. All candidate risk variants were validated with 
Sanger sequencing. Segregation analysis was performed with all candidate risk variants 
for available family members.  
4.6 Meta-analyses of publicly available data (III, IV) 
Considering the large size of TTN and the resultant effect on titin variant interpretation, 
meta-analyses of TTNtv identified in reference populations and DCM patients were 
carried out. Here, a variant assessment strategy that prioritizes TTNtv affecting at least 
five transcripts of the gene was implemented. 
4.6.1 Meta-analysis of titin truncations in the reference population (III) 
The workflow implemented for this meta-analysis is described in detail in the original 
publication III. Inline releases as well as the latest (last) release of the 1000 Genome 
Project were accessed, and TTNtv – splice, nonsense and frameshift variants, were 
retrieved and used for analysis.  
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Figure 6. Bioinformatics variants filtering and characterization to identify candidate 
risk variants. 
Exonic boundaries of TTN were retrieved from the Ensembl Genome Browser 
(www.ensembl.org), and used to extract exonic variants from the three versions of the 
phase 1 variants call sets (V1, V2, V3), and the version 5 (V5) of the phase 3 variants call 
set available in the 1000 Genomes Project database. Only calls that passed all quality 
filters were used for downstream analysis. 
Considering the small cohort size of the 1000 Genomes Project, and in a bid to capture a 
complete map of population TTN truncations, TTNtv reported in two other well-annotated 
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databases – Exome Sequecing Project (ESP) [241] and ExAC [240], with over 6500 and 
60700 individuals respectively were used. As 1000 Genomes Project cohorts and ESP 
cohorts are part of the ExAC project cohorts, TTNtv reported 1000 Genomes Project or 
ESP call sets were compared with those reported in ExAC, and were either flagged or 
filtered. Variants located in novex-3 specific exon and exons specific to few transcripts of 
TTN were filtered before filtering for sequencing coverage/depth. See Figure 2 in the 
original publication III.  
4.6.2 Meta-analysis of titin truncations in large DCM cohort (IV) 
TTNtv identified in 1788 DCM patients from four different studies were aggregated, and 
the spectrum, type and location of TTNtv identified in DCM patients were compared with 
those reported in the over 60,000 Exome Aggregation Consortium (ExAC) reference 
population. Since various studies reported TTNtv in different transcripts, the amino acid 
position of each variant in different transcripts as reported by the various studies was 
converted to the respective position in the inferred Meta transcript (ENST00000589042) 
using the genomic location of the variants. This was done to allow the inclusion of exons 
and variants not present in the canonical transcripts (ENST00000591111), otherwise 
referred to as the principal cardiac long isoform (N2BA), with the Uniprot ID Q8WZ42. 
Uniprot’s online sequence alignment tool (http://www.uniprot.org) was used to align the 
protein sequences of the inferred Meta transcript downloaded from ensembl 
(www.ensembl.org) and the canonical transcript (Q8WZ42). Thus, protein domain 
annotation of the canonical transcript was transferred to the inferred meta transcript. 
 4.7 Statistical analyses 
All statistical analyses were done using R statistical software. The Shapiro–Wilk test was 
applied to assess whether data deviated from the normal distribution. Normally 
distributed, continuous variables were expressed as mean ± SD and non-parametric as 
median, and lower and upper quartiles. All categorical variables were depicted using 
relative frequency distributions. Characteristics of different groups such as patients with or 
without disease-causing mutation were compared using the chi-square test for categorical 
variables if appropriate; otherwise Fisher’s exact test was used. Freedom from appropriate 
ICD therapies, death, atrial fibrillation, and heart transplant were each estimated separately 
and cumulatively by using the Kaplan–Meier method. Kaplan-Meier curves were 
computed and compared using “survfit” and “coxph R functions respectively. Independent 
samples t-tests combined with Levene’s tests were used for comparison between the 
groups for all continuous variables and Mann–Whitney U tests were used for non-
parametric variables. Differences were considered significant if the two-sided p-value was 
<0.05.  
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5. Results and discussions 
5.1 Gene expression profile associated with loss of PPARγ  
To reveal global gene expression changes associated with loss of PPARγ in human 
PMVEC, RNA sequencing was used to capture mRNAs abundance for all annotated genes 
from the ENSEMBL v72 annotation of the human genome (hg19). 
 
High-throughput sequencing technology is rapidly emerging as the standard for measuring 
RNA expression levels [260]. With the main goal of identifying differentially expressed 
genes between two or more conditions, RNA-Seq is impacting almost every field in life 
sciences and is now being adopted for clinical use [261]. Expression level measurement in 
RNA-Seq is different from gene probe-based methods, such as microarrays. While the 
expression signal of a transcript is limited by the sequencing depth and is dependent on the 
expression levels of other transcripts in RNA-Seq, probe intensities are independent of 
each other in array-based methods. This and other technical differences have formed the 
rationale for the development of a growing number of statistical algorithms that 
implement a variety of approaches for normalization and differential expression (DE) 
detection. 
5.1.1 Differentially expressed genes (DEG) 
Three methods – BaySeq, DESeq and EdgeR, were used to estimate differentially 
expressed genes between PPARγ deficient human PMVECs and the control. This was 
done to reduce false positive results as a result of the varying sensitivities of the 
algorithms. A total of 1030 genes were identified as being statistically differentially 
expressed by all the three methods (Figure 7). This corresponds to 38.6% of the total 
genes identified as being differentially expressed by all the three tools, and accentuates the 
need for the use of a combination of tools in such analysis.  BaySeq had the highest 
number, 946,  of unique DEG , while DESeq had the least, 12. Of note, 485 DEGs jointly 
identified by DESeq and EdgeR were not detected by BaySeq. In order to be conservative, 
all DEGs identified by at least two out of the three methods were included in the 
downstream analyses. Unsupervised hierarchical clustering of the top 50 differentially 
expressed genes is shown in Figure 8. 
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Figure 7. Venn diagram showing the degree of agreement between the methods. 
Differential gene expression analysis was done with three different tools. 
Genes detected by at least two out of three methods with the set thresholds 
were regarded as being significantly differentially expressed. 
 
 
 
 
Figure 8. Differential gene expression profile showing the heatmap of top 50 
differentially expressed genes. All genes that were found to be significantly 
differentially expressed between the two experimental conditions were 
retained for further analyses. 
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5.1.2 Pathways and gene ontology enrichment 
Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathway analysis revealed a significant enrichment of genes associated with cell-cycle 
control (Table 4). 
Table 4. Gene Ontology of significantly dysregulated genes based on RNA 
Sequencing. 
 
Gene Ontology analysis of significantly dysregulated genes from RNA Sequencing using a 
functional annotation tool from GOstats bioconductor package. Hypergeometric tests with 
Benjamini & Hochberg false discovery rate (FDR) were performed to adjust the P-value. 
 
KEGG analysis highlighted dysregulation of signaling pathways associated with cancer 
including p53 signaling pathway, TGF-beta signaling pathway, focal adhesion, PPAR 
signaling pathway, cell cycle jak-STAT signaling, ECM-receptor interaction, adherens 
junction, apoptosis, MAPK signaling pathway, and Wnt signaling pathway. Of particular 
interest is the Wnt signaling pathway in which ten genes including Neucrin/DRAXIN, 
osteopetrosis associated transmembrane protein 1 (OSTM1), and GSK3β interaction 
protein (GSKIP) were differentially expressed in PPARγ-depleted ECs compared to the 
control cells. Neucrin has been reported to play an inhibitory role in the stabilization of β-
catenin and directly reduce cell migration [262, 263]. OSTM1 enhances Wnt signaling 
through the regulation of β-catenin/Lef1 interaction. Down regulation of OSTM1 inhibits 
Wnt/β-catenin signaling [264].   
5.1.3 Loss of PPARγ in mature ECs causes angiogenic defect via 
downregulation of E2F1 
In a quest to understand how PPARγ regulates Wnt target genes (Neucrin, OSTM1, 
GSKIP) that were differentially expressed, an in silico promoter analyses was carried out 
to show if the genes had any canonical peroxisome proliferator hormone response 
elements (PPREs). However, the analyses showed that none of the genes had any 
Functional Category Gene Ontology Term # of Genes FDR 
SP_PIR_KEYWORDS Cell division 55 1.74E-15 
SP_PIR_KEYWORDS Cell cycle 74 6.16E-15 
SP_PIR_KEYWORDS Mitosis 43 1.55E-13 
SP_PIR_KEYWORDS Kinetochore 20 2.82E-07 
SP_PIR_KEYWORDS Phosphoprotein 452 2.01E-04 
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canonical PPREs. In silico promoter analysis was later combined with the bioinformatics 
approach to search for transcription factors that could potentially regulate GSKIP. With 
this approach, a total of 30 potential transcriptional regulators of GSKIP were identified. 
Previous ChIP-chip profile [29] and RNA expression profile of PPARγ-silenced ECs were 
compared with the 30 potential transcription regulators of GSKIP to identify TFs that 
regulate GSKIP and at the same time, downstream target of PPARγ. With this approach, 
E2F1 was identified as potential TF that fulfills the two conditions.   
 
With the identification of E2F1 as potential regulator of GSKIP and also a downstream 
target of PPARγ, it was hypothesized that downregulation of E2F1 in ECs should 
downregulate GSKIP, and reduce levels of β–catenin. Interestingly, E2F1-silenced ECs 
showed a significant attenuation of GSKIP expression, more active GSK3β, and reduced 
levels of β–catenin (data not shown). Interestingly, the ChIP assay analysis and previous 
ChIP-chip results showed that PPARγ was able to bind to E2F1 promoter area [29]. Put 
together, these results showed that PPARγ plays an important role in sustaining angiogenic 
potential in mature ECs through E2F1. Disruption of PPARγ-E2F1 axis dysregulates Wnt 
signaling through GSKIP gene. 
5.2 Genetic landscape and profiling of Finnish dilated 
cardiomyopathy 
Until now, DCM genetics studies in Finland have been single gene or subgroup testing, 
since it was impossible to sequence a wider array of genes until lately, when next-
generation sequencing (NGS) technologies enabled a comprehensive testing [265-267]. 
This study is the first clinical study on Finnish DCM patients utilizing a novel targeted 
NGS approach called OS-Seq. The Pan Cardiomyopathy OS-Seq panel represents the 
most comprehensive cardiomyopathy panel targeting over 100 genes associated with 
cardiomyopathies.  Based on 101 genes in the panel, all known cardiomyopathy-
associated mutations from different mutation databases and literature (Table 5) were 
collected and stored in an in-house relational cardiomyopathy database  (CMdb). Over 
65% of the mutations are single base substitutions (SNP) with about 19% being insertion-
deletions (INDEL) and others being either copy number variations (CNV) or complex 
mutations. 
 
 
 
 
 
 
 
 
 
 
44 
Table 5. Distribution of cardiomyopathy-associated mutations in our in-house 
relational cardiomyopathy database  (CMdb). 
 
5.2.1 Overview of the study patients 
The Finn-DCM study cohort consisted of 145 DCM patients of Finnish origin recruited 
between 1999 and 2013 from Helsinki University Hospital. With a mean follow-up time 
of 6.2 years, the patients were mainly middle-aged at the time of diagnosis, and were 
carefully evaluated by medical history and clinical examination. The clinical 
characteristics of the familial and sporadic cases presented in Table 6 represents those 
observed at the time of diagnosis. There were no statistically significant differences in the 
clinical features of sporadic and familial cases. 
5.2.2 OS-Seq in identifying disease-causing mutation 
Genomic DNA samples isolated from 145 DCM patients were sequenced using the OS-
Seq technology. The technology yielded a high coverage of the target region (median 
coverage 410x and 99.42% of the nucleotides were sequenced at least 15x read depth) 
(Figure 9).  
 
 
 
 
Mutation subtype # of Mutation (%) 
SNP 
Missense 3331 (43.8%) 
Nonsense 902 (11.8%) 
Splicing 693 (9.1%) 
UTR 39 (0.5%) 
Silent 21 (0.3%) 
INDEL 
1 - 5bp 1159 (15.2%) 
6 - 20bp 189 (2.5%) 
21 - 100bp 71 (0.9%) 
101 - <1kb 33 (0.4%) 
CNV (>1kb) 1094 (14.4%) 
Complex 71 (0.9%) 
Repeats 9 (0.1) 
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Table 6. Clinical characteristics of subjects with DCM in relation to DCM type 
(familial vs. sporadic) and mutation status in the Finnish DCM cohort 
(n=145). 
 
BMI, body mass index; LVEF, left ventricular ejection fraction; LVEDD index, left 
ventricular end-diastolic diameter indexed to body surface area; ICD, implantable 
cardioverter defibrillator; CRT, cardiac resynchronization therapy; CRT-D, pacemaker 
with CRT+ICD. All data are presented in percentages or mean ±SD. 
 
Genotyping with GATK Unified Genotyper in multi-sample mode, a total of 1513 variants 
present in 145 subjects was obtained. After implementing a variant filtering strategy 
(Figure 5) in which all synonymously coding single-nucleotide substitutions were 
excluded and the rest filtered for their Phred-scaled quality (at least 400) before excluding 
common polymorphisms based on variants reported in 1000 Genomes, ESP, ExAC and 
SISu, a total of 167 rare exonic (131 missense, 13 nonsense, 17 frameshift-indel, and 6 in-
frame indel) and 2 splice-site variants was obtained as candidates for further analyses. 
With 79.2% (134/169) being private, 81.1% (119/145) and 46.9% (68/145) carried at least 
one rare and multiple rare variants in the target genes respectively (Table 7). Of the rare 
missense variants, 32.8% (43/131) were predicted deleterious. After clinical variant 
assessment, 38 variants were classified as “pathogenic” or “likely pathogenic” leading to a 
 
Familial 
(n=63) 
Sporadic 
(n=82) 
Mutation 
Positive (n=50) 
Mutation 
Negative (n=95) 
Age at diagnosis (yrs) 44.3±12.2 46.8±11.7 43.7±11.8 46.7±11.9 
BMI (kg/m2) 26.0±4.3 25.6±3.9 24.9±3.9 26.2±4.2 
LVEF (%) 25.2±10.2 23.0±7.5 24.9±10.4 23.5±7.9 
LVEDD index (mm/m2) 35.1±5.2 36.9±5.1 36.2±3.7 35.3±5.7 
Alive (%) 79.40% 85.40% 79.6% 84.4% 
None  50.00% 56.10% 57.1% 52.1% 
Pacemaker 11.10% 3.70% 10.2% 5.2% 
ICD 19.00% 17.10% 16.3% 18.8% 
CRT 7.90% 6.10% 6.1% 7.3% 
CRT-D 11.10% 17.10% 10.2% 16.7% 
Any ICD (ICD+CRT-D) 30.10% 34.20% 26.5% 35.5% 
Angiography 76.20% 80.50% 75.5% 80.2% 
Resuscitated (%) 22.20% 17.10% 20.4% 18.8% 
Transplantation (%) 27.00% 31.70% 32.7% 28.1% 
Age at transplantation 49.7±10.3 46.9±10.4 45.9±8.8 49.2±11.1 
Atrial fibrillation (%) 47.60% 37.80% 51.0% 37.5% 
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Figure 9. Sequence coverage of dilated cardiomyopathy genes. Vertical axis is showing 
the target coverage for every gene, colour codes gives the read depth of 
coverage. The horizontal axis shows the median coverage in reads per gene 
(transparent blue polygon). 
diagnostic yield of 35.2% (familial: 47.6% vs. sporadic: 25.6%, P=0.004). Of note, 31.6% 
of the candidate risk variants identified in this study have been previously associated with 
DCM. These mutations were identified in sarcomere genes: titin (TTN), myosin, heavy 
chain 7 (MYH7), troponin T type 2 (TNNT2); nuclear lamina gene: lamin A/C (LMNA); Z-
disc/related, desmosomal, Ca2+ handling genes: desmoplakin (DSP), RNA-binding motif 
protein 20 (RBM20), dystrophin (DMD), and titin cap (TCAP). Distribution of disease-
causing mutations within these genes in Finn-DCM cohort is presented in Figure 10. 
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Table 7. Multiple rare variants identified in single patients in Finn-DCM cohort. 
 
DCM, Dilated Cardiomyopathy; fDCM, familial DCM; sDCM, sporadic DCM 
 
 
 
Figure 10. Distribution of pathogenic and likely pathogenic variants among tested genes 
in patients with familial or sporadic dilated cardiomyopathy in the Finnish 
dilated cardiomyopathy study. “n” represents number of patients carrying a 
candidate risk variant in a particular gene. 
TTN gene carried the highest number of candidate risk variants. A total of 64 unique rare 
TTN variants (38 missense: 46 patients; 11 nonsense: 16 patients; 9 frameshift: 10 
patients; 1 consensus splice-site variant: 1 patient) was identified in 48% (71/145) of the 
Finn-DCM cohort.  Of note, 11 of the missense variants are novel based on ExAC 
database. However, as TTN missense variants are often considered as variants of unknown 
significance (VUS), only TTNtv – frameshift, nonsense and splice-site variants, predicted 
to cause loss of function were included in downstream analyses. In total, 17.2% (25/145) 
of Finn-DCM cohort carried a loss of function mutation in TTN (familial: 20.6% vs. 
sporadic: 14.6%). Consistent with the findings of Herman et al. [9], TTNtv identified in 
Number of 
rare variants 
Rare variant positive  
Finn-DCM patients (%) 
Rare variant positive  
fDCM patients (%) 
Rare variant positive  
sDCM patients (%) 
0 26 (17.9) 10 (15.9) 16 (19.5) 
1 51 (35.2) 19 (30.2) 32 (39.0) 
2 42 (28.9) 18 (28.6) 24 (29.3) 
3 11 (7.6) 7 (11.1) 4 (4.9) 
4 12 (8.3) 8 (12.7) 4 (4.9) 
5 3 (2.1) 1 (1.6) 2 (2.4) 
 
 
 
 
 
48 
Finn-DCM cohort were non-randomly distributed along the gene; instead, the majority 
62% (13/21) of the mutations were located in the large A-band region of the gene known 
to associate with thick filament. Of note, all but one of TTNtv predicted to cause loss of 
function in Finn-DCM cohort affected all transcript of TTN gene. Family segregation 
analysis in five families with TTNtv revealed positive segregation with the disease in all 
cases (data not shown). 
5.2.3 Recurrent variants in multiple dilated cardiomyopathy patients 
Although recent studies have identified same disease-causing variants in multiple DCM 
families [144, 145], majority of the disease-causing variants in Finn-DCM cohorts were 
unique to families. Nevertheless, a total of four disease-causing mutations were identified 
in multiple DCM patients. Given that DCM-causing mutations are often private or unique 
to families, allele frequencies of disease-causing variants identified in more than one Finn-
DCM family were compared with those identified in the largest available genetically 
matched control population (Finnish controls in ExAC) using Fishers’ exact test (Table 8). 
Notably, 2.1% (3/145) of the Finn-DCM cohort carried LMNA Ser143Pro mutation. The 
Ser143Pro mutation in LMNA has been reported to be common among Finnish patients 
with DCM. The Finnish founder mutation Ser143Pro phenotype is characterized by severe 
heart failure, progressive atrioventricular conduction defects, and sudden death [177]. 
Furthermore, 4.1% (6/145) of the Finn-DCM cohort carried Thr2104Glnfs*12 in DSP 
gene. This mutation has been reported to cause early childhood-onset multi-organ disease 
with severe DCM combined with skin, hair, and tooth abnormalities [268, 269]. Of note, 
one of the patients had a Finnish mother, and the family of the second patient came from 
Swedish west coast, a location of a large population of Finnish immigrants. Based on the 
previous reports, and the result in this study, the Thr2104Glnfs*12 in DSP represents a 
typical Finnish DSP founder mutation associated with DCM disease. 
Table 8. Pathogenic and likely pathogenic variants present in multiple DCM 
families. 
 
DCM, Dilated cardiomyopathy 
 
Gene Transcript Genomic 
Location 
Nucleotide 
Change 
Amino Acid  
Change 
Calls 
(N) 
ExAC 
(N) 
P-value 
LMNA ENST00000368300 1:156100478 c.427T>C p.Ser143Pro 3 0/3372 7.3E-05 
DSP ENST00000379802 6:7583804 c.6310delA p.Thr2104Glnfs*12 6 2/3372 1.5E-07 
TTN ENST00000589042 2:179453719 c.62733G>A p.Trp20911* 3 0/3372 7.3E-05 
TTN ENST00000589042 2:179419765 c.88421G>A p.Trp29474* 3 0/3372 7.3E-05 
 
 
 
 
 
49
5.2.4 Clinical characteristics and genotype-phenotype correlations 
The clinical features of mutation positive patients were statistically indistinct from those 
of the mutation negative patients (Table 6). Patients with TTNtv had larger left ventricular 
end-diastolic diameter (LVEDD) compared with LMNA mutation carriers (70 ± 8 mm vs. 
60 ± 10 mm, P = 0.03). However, LMNA mutation carriers had higher rate of pacemaker 
implantation, history of resuscitation, and atrial fibrillation compared to others with 
mutations in other genes. There was no significant difference in reaching the composite 
end point (cardiac transplantation and/or death from cardiac causes) among mutation 
positive vs. negative patients (P = 0.34, Figure 11A) or patients with disease-causing 
mutations in TTN vs. LMNA (P = 0.58, Figure 11B). 
 
 
Figure 11. Kaplan-Meier curve demonstrating freedom from adverse events (cardiac 
transplantation and death from cardiac causes). The mean follow-up time was 
6.2 years. Panel A shows Kaplan-Meier curve for patients with and without 
detected disease causing mutation and panel B comparison between patients 
with TTN vs. LMNA mutations. Hatch marks indicate patient age at last 
follow-up date in Finn-DCM study. 
5.2.5 Technological limitations 
Using a fast and cost-effective OS-Seq Pan Cardiomyopathy panel, a diagnostic yield of 
35.2% was obtained in the whole Finn-DCM cohort, thus, demonstrating the efficacy of 
comprehensive targeted sequencing panel in genetic diagnosis for a substantial proportion 
of DCM patients. Despite of many successes, there are a number of technological 
limitations to targeted NGS panels that should be noted. Genetic findings in NGS panels 
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are often restricted to a small number of genes in the panel and do not enable discovery of 
novel genes, and WGS and WES are better approaches for discovery of novel genes. In 
the Finn-DCM study, about 65% of the cohort did not carry candidate risk variants in the 
genes investigated. Further more, causal variants located outside of the captured regions 
(introns, untranslated (UTR) and regulatory regions) are missed. Moreover, genetic 
variations (e.g. structural rearrangements and CNVs such as repeats and larger deletions) 
that span more than one exon are not well detected. Nevertheless, methods have been 
emerging for the detection of CNVs from target NGS data [270-272]. 
5.3 Prevalence and relevance of titin truncations  
Truncating TTN variants, especially in the A-band region of TTN, represent a significant 
cause of DCM, and account for ~21% of DCM cases (familial: 25% vs. sporadic: 18%) 
[9]. These findings have revolutionized our understanding of DCM pathogenesis and 
improved the utility of genetic testing among these patients. However, clinical 
interpretation of these variants can be challenging, as these variants were thought to be 
prevalent in the general population.   
5.3.1 Assessment of truncating TTN variants 
As clinical interpretation of TTN truncating variants (TTNtv) identified in health and 
disease has been challenged by the existing inaccurate variant assessment strategy and 
uncertainty in the true frequency of TTNtv across the general population, a variant 
assessment strategy that prioritizes rare TTNtv affecting multiple or all isoforms of the 
gene was implemented. Recent study suggests that variants affecting only a subset of gene 
transcripts are less likely to cause loss of function than variants affecting all isoforms 
[273]. Consequently, the current variant assessment strategy prioritizes TTNtv affecting at 
least five transcripts of the TTN gene as likely candidate variant.  
 
A recent study on the cardiac effects of TTNtv catalogued TTN exon usage in human left 
ventricle (LV) using RNA-Sequencing and described it as proportion spliced-in (PSI: 
range, 0 to 1) – the proportion of transcripts that include a given exon. The authors found 
that TTNtv-containing exons in controls have lower PSI than TTNtv-containing exons in 
DCM patients. Interestingly, the implemented approach using the number of transcript 
affected correlates with the PSI (rho = 0.946). 
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 5.3.2 Titin truncations in the reference population 
Interpretation of genetic variants and findings has been greatly improved by availability 
and utilization of reference population genetic variant databases. A number of large-scale 
resequencing projects, e.g. 1000 Genomes Project, ESP, The Cancer Genome Atlas 
(TCGA), ExAC etc., have been initiated to extend our knowledge of SNPs, short INDELs 
and SVs, and relate these variants to human diseases. The 1000 Genomes and the ESP 
have been widely used in several studies to draw inferences on the map of human genetic 
mutations. Using the two databases, different studies have reported different estimates of 
the prevalence of TTNtv in the population [243, 274]. This has been due to quality and 
coverage of sequencing data on one side, and the number of individuals in the cohort on 
the other hand. Using the February 2012 release (phase 1 version 2) of the 1000 Genomes 
containing variants and phased genotypes across 1092 individuals from 14 different 
populations, Golbus et al. [274] estimated frameshift INDELs that disrupt TTN to be 
present in 3.2% (35/1092) of the cohort. Recently, Roberts et al. [243] reported a 
prevalence of 2% using a combination of 1000 Genomes call set (phase 1 version 3) and 
ESP call set.  
 
In order to show how quality and coverage/depth of sequencing in the various phases and 
releases of the 1000 Genomes Project have influenced the estimate of TTNtv frequency in 
the reference population, TTNtv that passed all quality filters as reported by the 1000 
Genomes Project from each version of the phase 1, and the version 5 of the phase 3 
releases were extracted and used to estimate the prevalence of TTNtv in each version. 
Interestingly, a marked reduction in both the number of TTNtv and TTNtv prevalence 
from the oldest to the latest release of the project was observed (Figure 12). 
 
As knowledge of the map and prevalence of TTNtv is critical when interpreting genetic 
results, the latest release of the 1000 Genomes Project, ESP, and for the first time, ExAC 
cohort datasets were utilized. Using the workflow as previously described (study III), the 
frequencies of TTNtv in the datasets before and after filtering were estimated (Table 9). 
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Figure 12. Influence of 1000 genomes project evolution on titin truncation prevalence. 
Abbreviations: P1V1 – phase 1 version 1; P1V2 – phase 1 version 2; P1V3 – 
phase 1 version 3; P3V5 – phase 3 version 5. 
Table 9. Distribution and burden of TTN truncations in publicly available reference 
populations. 
 
Titin truncations in 1000 Genomes project (Phase 3), Exome Sequencing Project, and 
ExAC databases. The number of alleles and population prevalence for each variant is 
shown. Variants were filtered to exclude variants with low probability of pathogenicity 
(located in novex-3 specific and other exons with low expressions in LV). Abbreviations: 
1KG – 1000 Genomes project; ESP – Exome Sequencing Project; ExAC - Exome 
Aggregation Consortium; PSI – Proportion Spliced-In. 
 
 
Total TTN truncating Allele 
Excluding novex-3 specific, low PSI, 
and likely false positive variants 
1KG ESP ExAC 1KG ESP ExAC 
Population size 2504 6504 60706 2504 6504 60706 
Total TTNtv variant 29 66 470 9 16 173 
Individuals 46 612 813 10 19 219 
Prevalence (%) 
Population 1.837 9.409 1.339 0.399 0.292 0.360 
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When comparing the variants reported in the databases, only three splice-site variants 
were shared by both 1000 Genomes and ESP TTNtv call sets. This suggests the 
enrichment of population specific variants in ESP, as it is made up of primarily Americans 
either of European (EA) or African (AA) origin. Of note, over 50% of TTNtv (1000 
Genomes: 52% - 17/33; ESP: 54% - 36/66; ExAC: 53% - 247/470) found in the 
populations were located in exons that are unique to only few transcripts and estimated to 
have low probability of pathogenicity.   
 
As the ESP cohort is made up of primarily American populations, the 1000 Genomes 
Project dataset is limited by cohort size, and some subtypes of TTNtv were absent in 
either 1000 Genomes or ESP call sets (data not shown), the ExAC database gave the most 
reliable estimate. In the ExAC database the prevalence of TTNtv affecting all transcripts 
of the gene was 0.36% (0.315% - 0.413%, 95% CI). 
5.3.3 Ethnic distribution of TTN truncating variants  
Test for equality of proportions without continuity correction was used to test for the 
differences in the prevalence of TTNtv among ethnic groups in the ExAC cohort. 
Frequencies of TTNtv vary significantly between different ethnic groups (African 
population [AFR]: 0.46%, American population [AMR]: 0.50%, European population 
[EUR]: 0.27%, Asian population [AS]: 0.53%;?? ? ???? ?????).  European population 
has the least frequency of TTNtv among all the populations. Finnish European population 
(FIN) has a lower but statistically indistinct frequency of TTNtv when compared with the 
frequency in non-Finnish Europeans (NFE) (FIN: 0.12% vs. NFE: 0.28%%;?? ? ?????). 
The frequency of TTNtv in the Asian population, being the highest, is notably almost 
twice that of EUR. The frequency of TTNtv in East Asian population (EAS), though 
lower, is not significantly different from that of the South Asian Population (SAS) (EAS: 
0.37% vs. SAS: 0.62%;?? ? ?????). Golbus et al. [274] recently reported that Asians have 
significantly more TTN protein altering variants (PAV) than all other ethnic groups (28.76 
variants/individual). In this study, a higher frequency of TTNtv was found in the Asians. 
Put together, the Asian population (SAS in particular) seems to be more prone to 
mutations in TTN than other ethnic groups. This probably could explain why the 
prevalence of heart failure (HF) is higher in SAS compared to other part of the world 
[275].  
5.3.4 Spectrum of nonsense TTN SNPs in reference population 
Nonsense mutations account for 19.7% of disease-associated single base pair substitution 
affecting gene coding regions and ~11% of all described gene lesions causing human 
inherited disease as catalogued in the Human Gene Mutation Database (HGMD November 
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30, 2015; www.hgmd.org). Pathological nonsense mutation reported in HGMD resulting 
in TGA, TAG, and TAA occur in different proportion compared to the spectrum of TTN 
nonsense mutations in ExAC (Figure 13). Proportion of TAG nonsense mutations is 
higher in HGMD nonsense variants compared to TTN nonsense variants in ExAC (41.9% 
vs. 13.9%; ? ? ????? ?????). While TTN variants in ExAC have a higher proportion of 
TGA nonsense mutations (61.1% vs. 36.2%; ? ? ????? ?????), the proportion of TTN 
TAA nonsense variants in ExAC is statistically indifferent from HGMD nonsense 
mutations (25% vs. 21.9%; ? ? ????).  
 
 
 
Figure 13. Comparison of spectrums of nonsense mutations in the generation population 
with pathological nonsense mutations reported in HGMD.  
Out of the twenty-three possible ways to change codons into stop codons (nine, seven and 
seven for the first, second and third positions, respectively), twenty-one were found in 
reference population TTN nonsense variants, with CGA/TGA (resulting from methylation-
mediated deamination) accounting for 47.2% of the total TTN as against 19.8% in HGMD 
(? ? ????? ?????). The cytosine-guanine (CpG) dinucleotide, though under-represented 
in vertebrate genomes, has been reported to be a hotspot for pathological mutations in the 
human genome [276, 277]. This hypermutability is related to its role as the major site of 
cytosine methylation with the attendant risk of spontaneous deamination of 5-
methylcytosine (5mC) to yield thymine [278]. In this study, a significant proportion, 62%, 
of reference population nonsense variants are located at TTN A-band. Of note, a 
significant proportion of TTN Arg/* CpG hotspot mutations have been reported as germ 
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line mutations identified in various cancer cells. This highlights the fact that the CpG is a 
critical hotspot for both germline and somatic mutations. 
 
Epigenetic mechanisms are increasingly being recognized as causes and modulators of 
human disease, and a number of studies have reported differential DNA methylation 
patterns in CG dinucleotides located at the promoter, intragenic, gene bodies CpG islands 
and exon regions of cardiac muscle isoforms of genes in human end-stage cardiomyopathy 
[150-152]. Moreover, Meurs & Kuan [152] reported a significantly higher mean 
methylation level of CpGs in MYBPC3, a common causal gene for hypertrophic 
cardiomyopathy than in the skeletal muscle isoform of the gene (MYBPC2)  (P < 0.0001). 
These observations highlight the unique aspects of this cardiac gene may result in 
increased genetic mutability, and as such, evaluation of the methylation levels of TTN, and 
other DCM-associated genes are warranted in DCM patients. 
5.3.5 Interpretation of TTN splice region variants 
Differential splicing in regions with variable sarcomere ultrastructures accounts for the 
variable structures of TTN I-band in different tissues [279]. In a bid to characterize 
essential splice and other splice region variants that might contribute to disease 
development, the position (1 - 6bp into the intronic region, 1 - 2bp being essential splice 
site variants) and frequency of all TTN essential splice-site and splice-region variants in 
the population were examined and compared. A total of 373-splice site/region was 
identified in ExAC. However, 13.1% (49/373) of the splice site/region variants are located 
in the essential splice site and the bulk are located >2bp into the intronic region. Notably, 
88.8% (175/197) of the splice variants affecting A-band exons were non-essential splice-
site variants. Of the essential splice site variants, 83.7% (41/49) were private. In contrast, 
non-essential splice-site variants have higher proportion of low-frequency variants when 
compared to essential splice-site variants (? ? ???? ?????) (Figure 14). While essential 
splice-site variants were predominantly private, it was observed that allele copies of non-
essential splice-site variants increase as the distance increases from the essential splice-
site. This data together with the report of lower enrichment of noncanonical splice variants 
in DCM compared to canonical splice variants by Roberts et al. [243] confirms that 
clinical interpretation of non-essential splice site variants in TTN gene is difficult and 
these variants should not be claimed deleterious without RNA level evidence of splicing 
defect. 
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Figure 14. Allele frequency spectrums of TTN population splice site/region variants. TTN 
population non-essential splice-site variants (>2bp) have significantly lower 
proportion of private variants and higher proportion of low-frequency 
variants compared to essential splice-site variants (? ? ????? ?? ? ????
???????respectively). The P-values are shown for comparison between essential 
splice-site (1 - 2bp) and non-essential splice-site variants: 3 – 4bp (red), 5 – 
6bp (green), and (blue) for combined comparison 
5.3.6 Titin truncations in dilated cardiomyopathy patients 
Truncating TTN mutations, especially in A-band region, represent the most common cause 
of dilated cardiomyopathy (DCM). TTN truncating variants (TTNtv) - nonsense, 
frameshift and consensus splice site, have previously been estimated to be responsible for 
approximately 25% of familial cases of idiopathic dilated DCM and 18% of sporadic cases 
in a large cohort of subjects. This is a higher percentage than predicted for all other (>40) 
genes reported to be linked to DCM put together. However, after the initial report by 
Herman et al.[9], other studies have been reporting lower proportion between 14.1 – 
17.9% [242-244]. This disparity is largely due not only to population variations and 
proportion of familial cases in the individual cohorts, but also different variant 
interpretation approaches and uncertainties regarding the true prevalence of TTNtv in the 
population. 
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To address these issues, an expanded analysis on TTNtv reported in four major NGS-
based DCM studies and the largest available ExAC reference population was carried out.  
Using the total number and type of TTNtv reported by each study, the prevalence of 
TTNtv in each DCM cohort before and after implementing variant assessment strategy 
was estimated. Table 10 summarizes the number, type and distribution of TTNtv in DCM 
cohorts and ExAC reference cohorts. 
Table 10. Number, type and distribution of TTNtv in DCM cohorts and controls.  
 
Numbers (proportions) of subjects with a TTNtv are shown for each cohort before and 
after critical variant assessment to include only variants affecting ≥5 transcripts of TTN. 
Comparison between DCM cohorts and the ExAC cohort were assessed by Fisher’s exact 
test. * Other splice region variants were excluded, as their effects on splicing were not 
confirmed by the authors. 
 
TTNtv identified in 1788 DCM patients was aggregated and a total prevalence of 17.3% 
was obtained before implementing the variant assessment strategy. Implementing the 
variant assessment strategy, only 91% (222/243) of all TTNtv identified in DCM patient 
fulfilled this criterion. Of note, after implementing current variant assessment/ 
interpretation strategy, the proportion of TTNtv positive DCM patient in cohort A reduced 
to 18.9%; 13.8% in cohort B; 15.0% in cohort C; and remained unchanged in cohort D 
(17.2%) (Table 10). Twenty-three variants – seven frameshift; nine nonsense; and 3 splice 
variants, were identified in at least two cohorts, with the highest overlap occurring 
between cohorts A and C sharing nineteen TTNtv. Cohorts A and B have only one TTNtv 
in common while cohorts B and C shared three TTNtv. Of note, cohort D representing the 
  
Cohort A 
(n=312) 
Cohort B 
(n=639) 
Cohort C 
(n=692) 
Cohort D 
(n=145) 
All DCM 
cohorts 
(n=1788) 
ExAC 
cohort 
(n=60706) 
P-value DCM  
Versus  
Controls 
Before variant assessment 
TTNtv, n 62 76 113 21 243 470   
TTNtv +ve, n (%) 68 (21.8) 90 (14.1) 124 (17.9) 25 (17.2) 309 (17.28) 813 (1.34) 6.3 x 10-203 
Variant type, n (%)     
Frameshift variants 20 40 54 10 124 (6.94) 258 (0.42) 9.1 x 10-94 
Nonsense variants 28 46 46 16 136 (7.60) 258 (0.42) 5.8 x 10-107 
Essential splice site 16 4 21 1 42 (2.35) 297 (0.49) 2.3 x 10-15 
Other splice 
region* 4 - 3 - 7 (0.39) -   
      
After variant assessment (Including only variants affecting ≥5 transcripts), n (%) 
TTNtv, n 54 74 96 19 222 173   
TTNtv +ve, n (%) 59 (18.9) 88 (13.8) 106 (15.0) 25 (17.2) 278 (15.55) 219 (0.36) 4.1 x 10-295 
Variant type, n (%)     
Frameshift variants 19 39 52 8 118 (6.60) 95 (0.16) 2.6 x 10-123 
Nonsense variants 28 45 45 16 134 (7.49) 67 (0.11) 3.8 x 10-156 
Essential splice site 12 4 9 1 26 (1.45) 58 (0.09) 4.4 x 10-20 
      
Distribution by sarcomere domain, n (%)  
Z-band - 2 - 1 3 (0.17) 19 (0.03) 2.4 x 10-02 
I-band 5 19 17 4 45 (2.52) 40 (0.07) 1.9 x 10-46 
A-band 54 61 84 20 219 (12.25) 120 (0.19) 1.3 x 10-251 
M-band - 6 5 - 11 (0.62) 33 (0.05) 3.2 x 10-08 
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Finnish DCM patients shared no variant with the other cohorts (Figure 15). Interestingly, 
83% (202/243) of the TTNtv identified in DCM cohort were private. Summed together, 
15.6% of the multi-cohorts DCM patient carried a clinically relevant TTNtv. This 
highlights a possible over-estimation of the contribution of TTNtv to DCM, though the 
current estimate could be higher when considering only those with family history of 
DCM. 
 
 
 
Figure 15. Venn diagram illustrating the number and degree of overlap between TTNtv 
identified in different DCM cohorts.  
5.3.7 Distribution of TTNtv in DCM patients and in the general population 
When comparing TTNtv in DCM patients with those identified in ExAC control 
population, a total of twenty-two variants was identified common to both groups (not 
shown). Interestingly, 64% of such variants in the ExAC cohorts were private. Of note, 
19% (88/470) of the TTNtv identified in the ExAC reference population are unique to 
novex-3 isoform specific exon, and are likely benign.  
 
To validate and expand on the previous finding that TTNtv in DCM patients are clustered 
within A-band of TTN [9], the prevalence, spectrum and distribution of TTNtv in DCM 
patients were compared with those observed in ExAC control cohort before and after 
variant assessment (Table 10).  
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Despite the observed decline in both the number and prevalence of TTNtv in multi-cohorts 
DCM patients after variant assessment, it was observed that TTNtv affecting all transcripts 
of the gene were more prevalent in patients with DCM (278 of 1788 – 15.6%) compared 
with controls subjects (219 of 60706 – 0.4%; P = 4.1 x 10-295; OR = 50.8; 99% confidence 
interval: 39.72 – 65.05) (Figure 16). When assessing the variant type, nonsense variant 
occurred in 7.5% of DCM patients compared with 0.15% of the control subjects (P = 3.8 x 
10-156; OR = 73.3; 99% confidence interval: 49.34 – 110.81) (Table 10).  
 
In line with the previous report of A-band enrichment of TTNtv in DCM patients [9, 243, 
244, 280], a non-random distribution of TTNtv within and between study groups was 
observed (Figure 15). TTN A-band was enriched for TTNtv in DCM patients compared 
with ExAC reference cohort (P = 1.3 x 10-251; OR = 70.4; 99% confidence interval: 52.08–
96.35). Furthermore, our data showed also a significant I/A-band junction enrichment of 
TTNtv in DCM patients as compared with reference population (P = 1.9 x 10-46; OR = 
39.1; 99% confidence interval: 21.77–70.79). Of note, the significance of the enrichment 
increased after implementing our variant assessment strategy (Table 10). 
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6. Conclusions and future perspectives 
Advances in high-throughput sequencing technology coupled with the declining trend of 
cost per base pair have triggered wide adoption of NGS to address questions across the 
spectrum of biomedical and life science research, as the technologies provide 
opportunities to characterize individual genomic landscapes and identify mutations 
relevant for diagnosis and therapy. Due to the massively parallel nature of the 
technologies, enormous amount of data are generated, thus, giving rise to analytical and 
interpretative challenges that have the potential of limiting widespread use of the 
technologies. The studies presented herein focused on addressing the bioinformatics 
challenges of clinical genome sequencing, with the aim of demonstrating the utility of 
NGS panels in the genetic diagnosis of genetically heterogeneous group of disorders with 
emphasis on DCM among Finnish patients. 
 
1. Beyond the capability of RNA-sequencing for gene expression quantification is 
the choice of right tools and methods for identifying differential gene 
expression. In this study, three tools were used to quantify global gene 
expression changes associated with loss of PPARγ in human PMVEC, and the 
degree of agreement between the tools was 38.6% when considering 
differentially expressed genes identified by all the three tools. In view of this, it 
is recommended that a combination of tools should be used in estimating 
differentially expressed genes for optimal results. Furthermore, bioinformatics 
analyses further reveal that PPARγ-mediated regulation of EC homeostasis is 
tightly linked to Wnt and beta catenin pathways. 
 
2. OS-Seq based Pan-Cardiomyopathy gene panel targeting 101 genes provided a 
high and more uniform coverage of the target regions, with 99.0% sensitivity 
and 100% accuracy. Using the technology, the diagnostic yield in the Finnish 
patients with DCM was 35.2% (familial cases: 47.6%, sporadic cases: 25.6%) 
when considering only “pathogenic” and “likely pathogenic” variants as 
disease causing. By using a rigorous clinically oriented bioinformatics filtering 
coupled with the use of matched-population reference individuals, 
interpretative challenges that come with large panel size was tackled, thus, 
demonstrating that panel size did not influence diagnostic yield.  
A mutation in DSP, Thr2104Glnfs*12, was identified in 4.1% of Finn-DCM 
cohort. Considering its rarity in the reference population, it was concluded that 
the mutation represents the first Finnish DSP founder mutation associated with 
DCM disease. This with the previously reported LMNA Finnish founder 
mutation (p.Ser143Pro), also identified in this study (2.1%), could represent 
genomic targets and/or markers for the development of novel prognostic, 
diagnostic and possibly even individualized therapeutic approaches against this 
deadly disease. 
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3. TTN truncations, especially in the A-band region, represent a significant cause 
of DCM, and it accounts for 17.2% of the Finn-DCM cohort. Truncations of 
TTN causing DCM were not randomly distributed along the gene, instead, the 
bulk were clustered in the A-band region of the gene. Although thought to be 
prevalent in the general population, the result of this study has shown that more 
than 50% of titin truncating variants (TTNtv) in the population have low 
probability of pathogenicity as they affect few transcripts of the gene and 
mostly unique to novex-3 isoform which is not expressed in the LV.  
In order to foster better clinical interpretation of TTNtv identified in diagnostic 
settings, a scheme that support classification of variants affecting at least five 
transcripts of TTN as likely candidate variant was developed, and it was 
recommended to classify such as disease causing when found to segregate with 
the disease within family. As this practical and effective scheme correlates with 
findings based on RNA-sequencing, this approach could be extended to other 
cardiomyopathy genes with more than one isoforms. 
 
4. Using a gene panel targeting 101 genes comprising of 51 known genes and 50 
candidate genes associated with DCM, a diagnostic rate of less than 50% was 
obtained even in the familial cases. The absence of a molecular diagnosis in 
more than half of the individuals assayed shows the limitations of targeted 
panels, which do not interrogate large genomic aberrations spanning more than 
one exon or located in the intronic and regulatory regions. Additionally, it 
suggests the need for gene discovery studies to identify novel genes in the 
pathogenesis of DCM.  
 
As the diagnostic yield with the current knowledge on DCM genetics is only about 35% 
among Finnish DCM patients even with a large gene panel, further studies on novel gene 
discovery are warranted.  
Considering the size of TTN and the background mutation, it has been very difficult to 
assess the role of missense mutation. Currently, missense mutations in this gene, being the 
major cause of DCM, are being ignored. Furthermore, most of the available variant 
prediction tools have failed in predicting the effects of TTN missense mutations. It would 
be interesting to explore this area as some of the missense mutations might be playing 
modifier roles in the pathogenesis of DCM. 
While analyzing nonsense mutations in TTN, an over-representation of Cga/Tga 
(arginine/nonsense-R/*) transitional change at CpG mutation hotspots was observed. The 
CpG mutation was the most frequent type of TTN nonsense mutation accounting for 
91.3% (21/23) of arginine residue nonsense mutation (R/*) at TTN A-band region. Based 
on this observation, it was hypothesized that epigenetic modification may play a role in 
the pathogenesis of DCM. These data suggest that evaluation of the methylation levels of 
TTN, and other DCM-associated genes may be warranted in DCM patients. 
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